CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | radical |
|
Accession: | CHEBI:26519
|
browse the term
|
Definition: | A molecular entity possessing an unpaired electron. |
Synonyms: | related_synonym: | Radikal; Radikale; free radical; freies Radikal; radical libre; radicales libres; radicals |
|
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
4-amino-TEMPO inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]; 4-amino-TEMPO inhibits the reaction [MPO protein results in increased degradation of Hydrogen Peroxide]; 4-amino-TEMPO inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; Heparin inhibits the reaction [4-amino-TEMPO inhibits the reaction [MPO protein results in increased chemical synthesis of Hypochlorous Acid]] |
CTD |
PMID:34085520 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
tempo carboxylic acid inhibits the reaction [MPO protein results in increased degradation of Hydrogen Peroxide] |
CTD |
PMID:34085520 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
tempol inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein] |
CTD |
PMID:25204689 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein]; tempol inhibits the reaction [AGT protein results in decreased export of Sodium]; tempol inhibits the reaction [AGT protein results in increased abundance of Oxygen]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased expression of RHOA protein]] tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [AGT protein results in increased expression of EDN1 mRNA]; tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol promotes the reaction [ATOX1 protein inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]] |
CTD |
PMID:14597645 PMID:17391658 PMID:17620961 PMID:18250367 PMID:18768397 PMID:22753205 PMID:29609002 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
ISO |
tempol affects the phosphorylation of AKT1 protein |
CTD |
PMID:24550650 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] |
CTD |
PMID:20530721 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
ISO |
tempol promotes the reaction [ATOX1 protein inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]] |
CTD |
PMID:22753205 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
tempol inhibits the reaction [ATP7A mutant form inhibits the reaction [AGT protein results in increased susceptibility to Acetylcholine]]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] |
CTD |
PMID:18768397 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression decreases expression |
ISO EXP |
tempol affects the expression of BAX protein tempol results in decreased expression of BAX protein |
CTD |
PMID:18714161 PMID:24550650 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
tempol affects the expression of BCL2 protein |
CTD |
PMID:24550650 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
tempol results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C4b |
complement C4B |
decreases expression |
ISO |
tempol results in decreased expression of C4B mRNA |
CTD |
PMID:19555370 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO EXP |
[tempol co-treated with UCF 101 co-treated with acetovanillone] inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]; tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP3 protein] tempol results in decreased expression of CASP3 protein |
CTD |
PMID:18714161 PMID:20153346 PMID:20371263 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP7 protein]; tempol results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:20371263 PMID:26177467 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
EXP |
tempol results in decreased expression of CASP9 protein |
CTD |
PMID:18714161 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein results in increased susceptibility to [tert-Butylhydroperoxide co-treated with Desoxycorticosterone co-treated with tempol] |
CTD |
PMID:12646410 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
tempol results in decreased expression of CCN2 mRNA |
CTD |
PMID:16685210 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
tempol results in decreased expression of CCND1 protein |
CTD |
PMID:26177467 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
tempol inhibits the reaction [Superoxides affects the localization of CD38 protein] |
CTD |
PMID:23940720 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
tempol promotes the reaction [CDKN1A protein results in increased susceptibility to Doxorubicin] tempol results in increased expression of CDKN1A protein |
CTD |
PMID:15601469 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
tempol results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
tempol results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
tempol results in decreased expression of CYBA mRNA |
CTD |
PMID:16685210 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
decreases expression |
EXP |
tempol results in decreased expression of CYBB; tempol results in decreased expression of CYBB mRNA |
CTD |
PMID:16685210 PMID:20943769 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [CYP2E1 protein results in increased reduction of Tirapazamine] |
CTD |
PMID:7710944 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
EXP ISO |
tempol results in decreased expression of EDN1 mRNA; tempol results in decreased expression of EDN1 protein tempol inhibits the reaction [AGT protein results in increased expression of EDN1 mRNA] |
CTD |
PMID:17391658 PMID:28039404 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
affects localization |
ISO |
tempol affects the localization of EPAS1 protein |
CTD |
PMID:24755467 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
tempol inhibits the reaction [sodium arsenate results in increased expression of EPO mRNA]; tempol inhibits the reaction [sodium arsenate results in increased expression of EPO protein] |
CTD |
PMID:36513130 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases response to substance |
ISO |
tempol results in decreased susceptibility to FANCD2 gene mutant form |
CTD |
PMID:22628295 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Foxo3 |
forkhead box O3 |
affects phosphorylation |
ISO |
tempol affects the phosphorylation of FOXO3 protein |
CTD |
PMID:24550650 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of FTH1 protein]]; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of FTH1 protein] |
CTD |
PMID:38454815 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [Aldosterone results in increased expression of GCLC protein] NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLC protein]]; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLC protein]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLC protein]] |
CTD |
PMID:24512358 PMID:25204689 PMID:38454815 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLM protein]]; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLM protein]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLM protein]] |
CTD |
PMID:38454815 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[tempol co-treated with Tobacco Smoke Pollution] results in increased expression of GPX2 mRNA; tempol promotes the reaction [Tobacco Smoke Pollution results in increased expression of GPX2 protein] |
CTD |
PMID:32726580 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression multiple interactions |
ISO |
tempol results in increased expression of GPX4 mRNA NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of GPX4 protein]]; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of GPX4 protein] |
CTD |
PMID:22221582 PMID:38454815 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of GSR protein] |
CTD |
PMID:15925750 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
EXP |
tempol inhibits the reaction [Sodium Chloride results in increased expression of HIF1A protein] tempol results in increased expression of HIF1A protein |
CTD |
PMID:12595275 PMID:20232302 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
tempol inhibits the reaction [Asbestos, Crocidolite results in decreased activity of HMGCR protein]; tempol inhibits the reaction [Vitamin K 3 results in decreased activity of HMGCR protein] |
CTD |
PMID:21257924 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
tempol results in increased expression of HMOX1 mRNA NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]]; tempol promotes the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of HMOX1 protein] [tempol co-treated with Tobacco Smoke Pollution] results in increased expression of HMOX1 mRNA; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein] |
CTD |
PMID:12595275 PMID:32726580 PMID:38454815 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
tempol inhibits the reaction [PRKAA2 protein affects the expression of HSPA5 protein] |
CTD |
PMID:21145922 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
multiple interactions |
ISO |
[tempol co-treated with UCF 101 co-treated with acetovanillone] inhibits the reaction [S-Nitrosoglutathione affects the localization of HTRA2 protein] |
CTD |
PMID:20153346 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases expression |
ISO |
tempol results in decreased expression of IKBKE protein |
CTD |
PMID:26177467 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IL10 mRNA] |
CTD |
PMID:32726580 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL17A mRNA] |
CTD |
PMID:32726580 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [Phenol results in decreased expression of IL1B mRNA] tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL1B mRNA] |
CTD |
PMID:16785328 PMID:32726580 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA] tempol inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:24296301 PMID:32726580 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
increases expression |
ISO |
tempol results in increased expression of IREB2 protein |
CTD |
PMID:18073202 |
|
NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
tempol inhibits the reaction [Benzene results in decreased phosphorylation of IRS2 protein] |
CTD |
PMID:30346588 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
tempol inhibits the reaction [Paraquat results in increased expression of JUN mRNA] |
CTD |
PMID:7662713 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] |
CTD |
PMID:20530721 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
tempol inhibits the reaction [LEP protein results in decreased activity of PON1 protein] |
CTD |
PMID:15829432 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions |
ISO |
tempol inhibits the reaction [LEPR gene mutant form results in decreased susceptibility to Acetylcholine] |
CTD |
PMID:19478208 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20056918 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20056918 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir322 |
microRNA 322 |
multiple interactions |
ISO |
tempol inhibits the reaction [Glucose results in decreased expression of MIR322] |
CTD |
PMID:25516495 |
|
NCBI chr X:132,806,594...132,806,688
Ensembl chr X:132,806,594...132,806,688
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity |
EXP |
tempol results in increased activity of MMP2 protein |
CTD |
PMID:17196988 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity |
EXP |
tempol results in increased activity of MMP9 protein |
CTD |
PMID:17196988 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of and results in increased activity of MPO protein] |
CTD |
PMID:32726580 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases ubiquitination |
EXP ISO |
tempol inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein] tempol results in decreased ubiquitination of NFE2L2 protein tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NFE2L2 protein] NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of FTH1 protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of GPX4 protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NFE2L2 protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLC protein]]; NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLM protein]]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NFE2L2 protein]]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein]]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLC protein]]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of GCLM protein]] |
CTD |
PMID:25204689 PMID:38454815 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased activity of NFKB1 protein]; tempol inhibits the reaction [Copper results in increased activity of NFKB1 protein] |
CTD |
PMID:16987042 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
tempol inhibits the reaction [Particulate Matter results in decreased expression of NFKBIA protein] |
CTD |
PMID:27128347 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [tempol results in increased phosphorylation of NOS1 protein]; tempol inhibits the reaction [lead acetate results in increased expression of NOS1 protein]; tempol inhibits the reaction [Phenol results in decreased expression of NOS1 mRNA] |
CTD |
PMID:11454931 PMID:16785328 PMID:20056918 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased expression of NOS2 protein]; tempol inhibits the reaction [Copper results in increased expression of NOS2 protein]; tempol inhibits the reaction [lead acetate results in increased expression of NOS2 protein] |
CTD |
PMID:11454931 PMID:16987042 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [lead acetate results in increased expression of NOS3 protein]; tempol inhibits the reaction [Sodium Chloride results in decreased expression of NOS3 protein] |
CTD |
PMID:11230275 PMID:11454931 PMID:20232302 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [Paraquat results in increased activity of ODC1 protein] |
CTD |
PMID:7662713 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pah |
phenylalanine hydroxylase |
decreases expression |
ISO |
tempol results in decreased expression of PAH mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [sodium arsenite results in increased expression of PECAM1 protein] |
CTD |
PMID:19033667 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [LEP protein results in decreased activity of PON1 protein] |
CTD |
PMID:15829432 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
tempol inhibits the reaction [PRKAA2 protein affects the expression of HSPA5 protein] |
CTD |
PMID:21145922 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [Glucose results in decreased expression of PRKG1 protein] |
CTD |
PMID:17320767 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
tempol inhibits the reaction [Ketoconazole results in increased expression of PRKN mRNA]; tempol inhibits the reaction [Ketoconazole results in increased expression of PRKN protein] |
CTD |
PMID:25787151 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [copper histidine results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Copper results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Lead results in increased expression of PTGS2 mRNA]; tempol inhibits the reaction [Mercuric Chloride results in increased expression of PTGS2 mRNA] |
CTD |
PMID:16987042 PMID:23415682 PMID:25596430 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
tempol inhibits the reaction [Benzene results in increased phosphorylation of RELA protein] tempol inhibits the reaction [copper histidine results in increased activity of RELA protein]; tempol inhibits the reaction [Copper results in increased activity of RELA protein] |
CTD |
PMID:16987042 PMID:30346588 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP ISO |
tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased expression of RHOA protein]] tempol inhibits the reaction [Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Asbestos, Crocidolite results in decreased prenylation of RHOA protein]; tempol inhibits the reaction [Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Vitamin K 3 results in decreased prenylation of RHOA protein] |
CTD |
PMID:18250367 PMID:21257924 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; tempol inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein] |
CTD |
PMID:29609002 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [[AGT protein modified form co-treated with AGTR1A co-treated with AGTR1B] results in increased expression of SERPINE1 mRNA]; tempol inhibits the reaction [Hydrogen Peroxide results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:17620961 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Skap2 |
src kinase associated phosphoprotein 2 |
decreases expression |
ISO |
tempol results in decreased expression of SKAP2 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:80,950,580...81,100,891
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions |
EXP |
tempol inhibits the reaction [Manganese results in increased expression of SLC12A2 protein]; tempol inhibits the reaction [Manganese results in increased oxidation of SLC12A2 protein] |
CTD |
PMID:25817889 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
ISO |
tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein] NFE2L2 protein affects the reaction [tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein]]; tempol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein]; tempol promotes the reaction [NFE2L2 protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of SLC7A11 protein]] |
CTD |
PMID:38454815 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
multiple interactions |
ISO |
tempol inhibits the reaction [Benzene results in increased expression of SOCS1 mRNA] |
CTD |
PMID:30346588 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
tempol inhibits the reaction [Desoxycorticosterone results in decreased expression of SOD1 protein] |
CTD |
PMID:12646410 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects expression multiple interactions |
ISO EXP |
tempol affects the expression of SOD2 protein tempol affects the reaction [SOD2 protein affects the susceptibility to Acetylcholine]; tempol inhibits the reaction [Capsaicin results in decreased activity of SOD2 protein]; tempol inhibits the reaction [Capsaicin results in increased expression of SOD2 protein modified form] tempol inhibits the reaction [Isoflurane results in decreased expression of and results in decreased activity of SOD2 protein]; tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of SOD2 protein] |
CTD |
PMID:15925750 PMID:17693941 PMID:19129394 PMID:20304815 PMID:24550650 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
tempol results in increased expression of TFRC protein |
CTD |
PMID:18073202 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression multiple interactions |
ISO EXP |
tempol affects the expression of TGFB1 protein tempol inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of TGFB1 mRNA] tempol inhibits the reaction [Aldosterone results in increased expression of TGFB1 mRNA]; tempol inhibits the reaction [Sodium Chloride results in increased expression of TGFB1 protein] |
CTD |
PMID:20232302 PMID:24550650 PMID:25204689 PMID:32726580 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP3 protein]; tempol inhibits the reaction [[sulindac sulfide co-treated with TNF protein] results in increased activity of CASP7 protein] tempol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; tempol inhibits the reaction [Tobacco Smoke Pollution results in increased expression of TNF mRNA] tempol inhibits the reaction [copper histidine results in increased expression of TNF protein]; tempol inhibits the reaction [Copper results in increased expression of TNF protein] |
CTD |
PMID:15795323 PMID:16987042 PMID:20371263 PMID:32726580 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
tempol results in increased expression of TP53 protein |
CTD |
PMID:15601469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
multiple interactions |
ISO |
tempol inhibits the reaction [Glucose results in increased expression of TRAF3 protein] |
CTD |
PMID:25516495 |
|
NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
multiple interactions |
ISO |
tempol inhibits the reaction [Arsenic Trioxide results in increased expression of TRPM4 protein] |
CTD |
PMID:31054354 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression increases expression |
EXP |
tempol results in decreased expression of UCP2 mRNA tempol results in increased expression of UCP2 protein |
CTD |
PMID:16685210 PMID:24591154 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:28993908 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases phosphorylation |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:28993908 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of H2AX protein Acetylcysteine inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of H2AX protein]; pyrazolanthrone inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of H2AX protein] |
CTD |
PMID:28993908 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases metabolic processing |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased metabolism of MAP1LC3B protein |
CTD |
PMID:28993908 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
U 0126 inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:28993908 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:28993908 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression |
ISO |
4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in decreased expression of SQSTM1 protein |
CTD |
PMID:28993908 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in increased expression of ATF4 mRNA 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of ATF4 mRNA] |
CTD |
PMID:21703327 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in decreased nitrosation of and results in increased ubiquitination of and results in increased degradation of BCL2 protein; [1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in decreased nitrosation of and results in increased ubiquitination of and results in increased degradation of BCL2 protein] which results in increased susceptibility to Chromates |
CTD |
PMID:16980304 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of BIRC5 protein] |
CTD |
PMID:35985571 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased cleavage of CASP3 protein] |
CTD |
PMID:30482226 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cav1 |
caveolin 1 |
decreases expression |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in decreased expression of CAV1 protein |
CTD |
PMID:19706615 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of CCND1 protein] |
CTD |
PMID:35985571 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:14607919 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased expression of CDH1 protein] |
CTD |
PMID:35985571 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of CEBPB protein alternative form] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of CEBPB protein alternative form] |
CTD |
PMID:30482226 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cldn5 |
claudin 5 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [9,10-phenanthrenequinone results in decreased expression of CLDN5 protein] |
CTD |
PMID:34391839 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of and results in increased phosphorylation of CTNNB1 protein] |
CTD |
PMID:35985571 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in increased expression of DDIT3 mRNA 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of DDIT3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of DDIT3 mRNA] |
CTD |
PMID:21703327 PMID:30482226 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:35985571 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of MYC protein] |
CTD |
PMID:35985571 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ptgis |
prostaglandin I2 synthase |
decreases activity |
EXP |
cPTIO decreases activity of Ptgis protein in the aorta |
RGD |
PMID:12964126 |
RGD:401960074 |
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of SNAI1 protein] |
CTD |
PMID:35985571 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of SNAI2 protein] |
CTD |
PMID:35985571 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
decreases response to substance multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole results in decreased susceptibility to TNFSF10 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [TNFSF10 protein results in increased abundance of Reactive Nitrogen Species] |
CTD |
PMID:20971099 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitroprusside results in increased expression of TRIB3 protein] |
CTD |
PMID:30482226 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in decreased expression of VIM protein] |
CTD |
PMID:35985571 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Acbd3 |
acyl-CoA binding domain containing 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ACBD3-AS1 mRNA] which results in increased expression of ACBD3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions |
EXP |
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical |
CTD |
PMID:16162655 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Ankar |
ankyrin and armadillo repeat containing |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in increased expression of ANKAR mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:48,141,534...48,215,400
Ensembl chr 9:48,141,391...48,215,616
|
|
G |
Arap1 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of ARAP1-AS1 mRNA] which results in increased expression of ARAP1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:155,748,622...155,814,186
Ensembl chr 1:155,748,652...155,814,184
|
|
G |
Cat |
catalase |
decreases response to substance multiple interactions |
ISO |
CAT protein results in decreased susceptibility to Hydroxyl Radical CAT protein inhibits the reaction [chromium hexavalent ion results in increased chemical synthesis of Hydroxyl Radical] |
CTD |
PMID:10421593 PMID:11678602 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catip |
ciliogenesis associated TTC17 interacting protein |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CATIP-AS1 mRNA] which results in increased expression of CATIP mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:75,945,960...75,953,618
Ensembl chr 9:75,945,961...75,953,607
|
|
G |
Cblif |
cobalamin binding intrinsic factor |
affects metabolic processing |
ISO |
CBLIF protein affects the metabolism of Hydroxyl Radical |
CTD |
PMID:11750760 |
|
NCBI chr 1:208,605,983...208,620,231
Ensembl chr 1:208,605,983...208,620,344
|
|
G |
Ccdc183 |
coiled-coil domain containing 183 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CCDC183-AS1 mRNA] which results in increased expression of CCDC183 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 3:8,428,784...8,438,948
Ensembl chr 3:8,428,787...8,437,194
|
|
G |
Cimap1c |
ciliary microtubule associated protein 1C |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNM1P35 mRNA] which results in increased expression of CIMAP1C mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:57,248,746...57,281,084
Ensembl chr 8:57,248,746...57,281,004
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of COL4A2-AS1 mRNA] which results in decreased expression of COL4A2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Coro1a |
coronin 1A |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of CORO1A-AS1 mRNA] which results in decreased expression of CORO1A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions increases chemical synthesis |
ISO |
[DCXR protein results in increased metabolism of 9,10-phenanthrenequinone] which results in increased chemical synthesis of Hydroxyl Radical DCXR protein results in increased chemical synthesis of Hydroxyl Radical |
CTD |
PMID:28595002 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of DDIT4-AS1 mRNA] which results in decreased expression of DDIT4 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddx59 |
DEAD-box helicase 59 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DDX59-AS1 mRNA] which results in increased expression of DDX59 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr13:47,876,258...47,901,214
Ensembl chr13:47,876,261...47,901,214
|
|
G |
Dlgap1 |
DLG associated protein 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DLGAP1-AS2 mRNA] which results in increased expression of DLGAP1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of DNMT3L mRNA |
CTD |
PMID:33656867 |
|
NCBI chr20:10,614,933...10,629,337
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC02019 mRNA] which results in increased expression of DOCK3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:107,552,462...107,903,527
Ensembl chr 8:107,552,463...107,903,514
|
|
G |
Dynlt2b |
dynein light chain Tctex-type 2B |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in increased expression of DYNLT2B mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:68,359,138...68,367,573
Ensembl chr11:68,358,263...68,367,499
|
|
G |
E2f8 |
E2F transcription factor 8 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of CSRP3-AS1 mRNA] which results in increased expression of E2F8 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Fam83f |
family with sequence similarity 83, member F |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNRC6B-DT mRNA] which results in increased expression of FAM83F mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:112,211,164...112,240,454
Ensembl chr 7:112,211,164...112,240,452
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FBXW7-AS1 mRNA] which results in increased expression of FBXW7 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 2:170,149,706...170,311,536
Ensembl chr 2:170,149,694...170,309,941
|
|
G |
Fhad1 |
forkhead associated phosphopeptide binding domain 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FHAD1-AS1 mRNA] which results in increased expression of FHAD1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 5:154,191,593...154,310,442
Ensembl chr 5:154,191,745...154,310,354
|
|
G |
Flnb |
filamin B |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FLNB-AS1 mRNA] which results in decreased expression of FLNB mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
|
|
G |
Flnc |
filamin C |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of FLNC-AS1 mRNA] which results in increased expression of FLNC mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
increases abundance multiple interactions |
ISO |
FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:27385396 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Foxc2 |
forkhead box C2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of FOXC2-AS1 mRNA] which results in decreased expression of FOXC2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Foxl2 |
forkhead box L2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LINC01391 mRNA] which results in increased expression of FOXL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:99,512,971...99,514,500
Ensembl chr 8:99,513,303...99,514,427
|
|
G |
Gcc2 |
GRIP and coiled-coil domain containing 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GCC2-AS1 mRNA] which results in increased expression of GCC2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr20:26,247,394...26,293,613
Ensembl chr20:26,247,404...26,293,613
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-AS1 mRNA] which results in increased expression of GK mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of GK-IT1 mRNA] which results in increased expression of GK mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gsn |
gelsolin |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of GSN-AS1 mRNA] which results in decreased expression of GSN mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Hoxb9 |
homeo box B9 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXB-AS4 mRNA] which results in increased expression of HOXB9 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Hoxc13 |
homeobox C13 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of HOXC13-AS mRNA] which results in increased expression of HOXC13 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:134,058,640...134,065,479
Ensembl chr 7:134,058,640...134,064,800
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]; Oxygen deficiency inhibits the reaction [HRAS protein promotes the reaction [[sodium bichromate results in increased abundance of chromium hexavalent ion] which results in increased abundance of Hydroxyl Radical]] |
CTD |
PMID:14971653 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Iapp |
islet amyloid polypeptide |
multiple interactions |
EXP |
IAPP protein promotes the reaction [[Copper co-treated with Ascorbic Acid] results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:23793354 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Icoslg |
inducible T-cell co-stimulator ligand |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of DNMT3L-AS1 mRNA] which results in increased expression of ICOSLG mRNA |
CTD |
PMID:33656867 |
|
NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,420...10,610,703
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of INSIG1-DT mRNA] which results in decreased expression of INSIG1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PICART1 mRNA] which results in decreased expression of ITGA3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Kiaa1614 |
KIAA1614 homolog |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of KIAA1614-AS1 mRNA] which results in increased expression of KIAA1614 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr13:67,388,916...67,427,392
Ensembl chr13:67,389,044...67,421,272
|
|
G |
Krt7 |
keratin 7 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of KRT7-AS mRNA] which results in decreased expression of KRT7 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
Lbx2 |
ladybird homeobox 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of LBX2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:115,591,974...115,593,859
Ensembl chr 4:115,591,974...115,594,132
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LIF-AS1 mRNA] which results in increased expression of LIF mRNA |
CTD |
PMID:33656867 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Mmel1 |
membrane metallo-endopeptidase-like 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of MMEL1-AS1 mRNA] which results in decreased expression of MMEL1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 5:165,431,278...165,461,716
Ensembl chr 5:165,431,343...165,461,716
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
decreases degradation |
ISO |
Hydroxyl Radical results in decreased degradation of MSR1 mRNA |
CTD |
PMID:9614211 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
ISO |
[[MT3 protein binds to Zinc] which co-treated with Ascorbic Acid] inhibits the reaction [Copper results in increased chemical synthesis of Hydroxyl Radical] |
CTD |
PMID:17389590 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of NGFR-AS1 mRNA] which results in increased expression of NGFR mRNA |
CTD |
PMID:33656867 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nucb1 |
nucleobindin 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of NUCB1-AS1 mRNA] which results in decreased expression of NUCB1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein] |
CTD |
PMID:14623030 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Osgepl1 |
O-sialoglycoprotein endopeptidase-like 1 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of OSGEPL1-AS1 mRNA] which results in decreased expression of OSGEPL1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:48,214,995...48,229,440
Ensembl chr 9:48,215,402...48,229,388
|
|
G |
Piwil2 |
piwi-like RNA-mediated gene silencing 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of PIWIL2-DT mRNA] which results in increased expression of PIWIL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:45,431,402...45,498,034
Ensembl chr15:45,431,703...45,497,702
|
|
G |
Pla2g4e |
phospholipase A2, group IVE |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLA2G4E-AS1 mRNA] which results in increased expression of PLA2G4E mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 3:107,132,540...107,198,609
Ensembl chr 3:107,132,541...107,198,233
|
|
G |
Plcl2 |
phospholipase C-like 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PLCL2-AS1 mRNA] which results in increased expression of PLCL2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:3,292,564...3,477,009
Ensembl chr 9:3,292,695...3,477,009
|
|
G |
Polh |
DNA polymerase eta |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of POLH-AS1 mRNA] which results in increased expression of POLH mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 9:14,778,355...14,813,210
Ensembl chr 9:14,777,888...14,812,723
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[[Iron co-treated with POR protein] results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; [[Iron co-treated with POR protein] results in increased metabolism of Paraquat] which results in increased abundance of Hydroxyl Radical; [POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical [POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical; Dimethyl Sulfoxide inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased abundance of Hydroxyl Radical] |
CTD |
PMID:21215309 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Prickle2 |
prickle planar cell polarity protein 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS1 mRNA] which results in increased expression of PRICKLE2 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of PRICKLE2-AS3 mRNA] which results in increased expression of PRICKLE2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:124,869,655...125,214,862
Ensembl chr 4:124,869,552...125,214,824
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[[Superoxides co-treated with Hydroxyl Radical] results in increased oxidation of LPA protein] which results in decreased secretion of SERPINE1 protein |
CTD |
PMID:11681624 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sh3rf3 |
SH3 domain containing ring finger 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of SH3RF3-AS1 mRNA] which results in decreased expression of SH3RF3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr20:26,765,278...27,099,261
Ensembl chr20:26,765,015...27,099,257
|
|
G |
Smad5 |
SMAD family member 5 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SMAD5-AS1 mRNA] which results in increased expression of SMAD5 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
|
|
G |
Syp |
synaptophysin |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of SYP-AS1 mRNA] which results in increased expression of SYP mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tab3 |
TGF-beta activated kinase 1 (MAP3K7) binding protein 3 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS1 mRNA] which results in increased expression of TAB3 mRNA; [[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TAB3-AS2 mRNA] which results in increased expression of TAB3 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr X:49,972,414...50,044,658
Ensembl chr X:49,972,330...50,042,056
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of THY1-AS1 mRNA] which results in decreased expression of THY1 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659
|
|
G |
Tlx2 |
T-cell leukemia homeobox 2 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of LBX2-AS1 mRNA] which results in increased expression of TLX2 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 4:115,573,736...115,576,097
Ensembl chr 4:115,573,799...115,575,642
|
|
G |
Tm4sf19 |
transmembrane 4 L six family member 19 |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in decreased expression of TM4SF19-AS1 mRNA] which results in decreased expression of TM4SF19 mRNA |
CTD |
PMID:33656867 |
|
NCBI chr11:68,372,945...68,386,192
Ensembl chr11:68,371,647...68,384,591
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TNFRSF10A-AS1 mRNA] which results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Ttc23l |
tetratricopeptide repeat domain 23-like |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of TTC23L-AS1 mRNA] which results in increased expression of TTC23L mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 2:59,476,666...59,538,313
Ensembl chr 2:59,476,669...59,538,282
|
|
G |
Upk1a |
uroplakin 1A |
multiple interactions |
ISO |
[[Hydroxyl Radical results in increased oxidation of dimethylselenide] which results in increased expression of UPK1A-AS1 mRNA] which results in increased expression of UPK1A mRNA |
CTD |
PMID:33656867 |
|
NCBI chr 1:85,859,672...85,870,147
Ensembl chr 1:85,859,671...85,870,354
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions increases abundance |
ISO |
[[Oxygen deficiency results in increased abundance of Hypoxanthine] affects the reaction [XDH protein affects the metabolism of Hypoxanthine]] which affects the abundance of Hydroxyl Radical XDH protein results in increased abundance of Hydroxyl Radical |
CTD |
PMID:7929072 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
ABCC1 protein affects the reaction [AGT protein results in decreased abundance of Nitric Oxide]; ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Glutathione]; ABCC1 protein promotes the reaction [Nitric Oxide results in increased secretion of Iron] |
CTD |
PMID:16679408 PMID:17272743 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP ISO |
ABCC2 affects the reaction [Ursodeoxycholic Acid results in increased secretion of Nitric Oxide] ABCC2 gene SNP affects the susceptibility to [Air Pollutants results in increased abundance of Nitric Oxide] |
CTD |
PMID:20683964 PMID:29681089 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acbd3 |
acyl-CoA binding domain containing 3 |
multiple interactions |
EXP |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions increases expression |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA] |
CTD |
PMID:10948087 PMID:16326922 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Aco1 |
aconitase 1 |
decreases expression multiple interactions |
ISO |
Nitric Oxide results in decreased expression of ACO1 mRNA STAT5A protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA]; STAT5B protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] |
CTD |
PMID:16886906 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
multiple interactions increases expression |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA] |
CTD |
PMID:10397678 PMID:16326922 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of ACTB mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adm |
adrenomedullin |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of ADM mRNA |
CTD |
PMID:16326922 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adm2 |
adrenomedullin 2 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of ADM2 mRNA |
CTD |
PMID:16326922 |
|
NCBI chr 7:120,393,179...120,394,965
Ensembl chr 7:120,393,179...120,396,331
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases abundance |
ISO |
ADRB2 protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:10580815 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
decreases secretion increases chemical synthesis increases activity increases abundance increases secretion decreases abundance multiple interactions |
ISO EXP |
AGT protein modified form results in decreased secretion of Nitric Oxide AGT protein modified form results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in increased activity of AGT protein modified form AGT protein results in increased abundance of Nitric Oxide AGT protein alternative form results in increased secretion of Nitric Oxide AGT protein results in decreased abundance of Nitric Oxide AGT protein alternative form promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; PD 123319 inhibits the reaction [AGT protein results in increased abundance of Nitric Oxide]; theaflavin-3,3'-digallate inhibits the reaction [AGT protein results in decreased abundance of Nitric Oxide]; Valsartan inhibits the reaction [AGT protein results in increased abundance of Nitric Oxide]; Valsartan inhibits the reaction [AGT protein results in increased secretion of Nitric Oxide] ABCC1 protein affects the reaction [AGT protein results in decreased abundance of Nitric Oxide] candesartan inhibits the reaction [AGT protein results in increased chemical synthesis of Nitric Oxide]; Hydrogen Sulfide promotes the reaction [AGT protein modified form results in increased chemical synthesis of Nitric Oxide]; Losartan inhibits the reaction [AGT protein modified form results in decreased secretion of Nitric Oxide]; troglitazone inhibits the reaction [AGT protein modified form results in decreased secretion of Nitric Oxide] |
CTD |
PMID:12198334 PMID:14597853 PMID:14620932 PMID:17272743 PMID:17666345 PMID:18551021 PMID:18990443 PMID:29084084 PMID:35406003 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
affects abundance |
EXP |
AGTR1A protein affects the abundance of Nitric Oxide |
CTD |
PMID:19151255 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
affects abundance |
EXP |
AGTR1B protein affects the abundance of Nitric Oxide |
CTD |
PMID:19151255 |
|
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
affects response to substance |
EXP |
AGTR2 protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:9374809 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization |
ISO |
Nitric Oxide affects the localization of AIFM1 protein |
CTD |
PMID:15126337 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of AIMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:221,151,907...221,175,458
Ensembl chr 2:221,151,904...221,175,728
|
|
G |
Aip |
aryl-hydrocarbon receptor-interacting protein |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of AIP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:201,408,002...201,419,220
Ensembl chr 1:201,407,288...201,419,122
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
AKT1 protein inhibits the reaction [Carbon Tetrachloride results in decreased abundance of Nitric Oxide] |
CTD |
PMID:18245901 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[ALDH2 protein affects the metabolism of and results in increased susceptibility to Pentaerythritol Tetranitrate] which results in increased abundance of Nitric Oxide |
CTD |
PMID:21156756 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
Nitric Oxide promotes the reaction [Reactive Oxygen Species results in decreased activity of ALOX5 protein] |
CTD |
PMID:12388339 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Angptl2 |
angiopoietin-like 2 |
decreases chemical synthesis |
ISO |
ANGPTL2 gene mutant form results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:27402837 |
|
NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
Nitric Oxide results in increased expression of ANXA5 protein |
CTD |
PMID:16024610 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoe |
apolipoprotein E |
decreases chemical synthesis |
ISO |
APOE gene mutant form results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:11397713 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Ibuprofen inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Indomethacin inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:11080519 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp2 |
aquaporin 2 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of AQP2 protein |
CTD |
PMID:17940347 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases response to substance |
ISO |
ASS1 protein results in increased susceptibility to Nitric Oxide |
CTD |
PMID:25033204 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
Nitric Oxide deficiency inhibits the reaction [Clofibrate results in increased expression of ATP1A1 protein] |
CTD |
PMID:15018640 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of ATP5F1B mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273
|
|
G |
Avp |
arginine vasopressin |
affects metabolic processing increases expression multiple interactions |
EXP |
AVP protein affects the metabolism of Nitric Oxide Nitric Oxide results in increased expression of AVP mRNA IL1B protein affects the reaction [AVP protein affects the metabolism of Nitric Oxide] |
CTD |
PMID:10460269 PMID:21171372 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of AXL mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
Nitric Oxide results in increased expression of B2M protein |
CTD |
PMID:15764486 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization multiple interactions decreases expression |
ISO EXP |
Nitric Oxide affects the localization of BAX protein Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in increased expression of and affects the localization of BAX protein] [Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein] Nitric Oxide results in decreased expression of BAX protein [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of BAX protein |
CTD |
PMID:10828028 PMID:14634119 PMID:22878015 PMID:25726415 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Nitric Oxide results in increased expression of BBC3 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
multiple interactions decreases phosphorylation |
EXP |
Nitric Oxide inhibits the reaction [BCAR1 protein binds to CRK protein] Nitric Oxide results in decreased phosphorylation of BCAR1 protein |
CTD |
PMID:12714323 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression affects expression multiple interactions |
ISO |
Nitric Oxide results in decreased expression of BCL2 protein Nitric Oxide affects the expression of BCL2 mRNA [3,5-dimethoxy-4'-hydroxystilbene results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 mRNA; [linsidomine results in increased abundance of Nitric Oxide] which results in increased expression of BCL2 protein; [Quercetin results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased expression of BCL2 protein; Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein; pimagedine inhibits the reaction [Nitric Oxide results in increased nitrosation of and results in decreased degradation of BCL2 protein] |
CTD |
PMID:7706495 PMID:10828028 PMID:15126337 PMID:16980304 PMID:17135264 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Nitric Oxide results in decreased expression of BCL2L1 protein Nitric Oxide results in increased expression of BCL2L1 mRNA GATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]; GATA5 protein promotes the reaction [Nitric Oxide results in increased expression of BCL2L1 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]; Nitric Oxide results in increased expression of and affects the localization of BCL2L1 protein |
CTD |
PMID:15126337 PMID:25726415 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:29775649 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases chemical synthesis multiple interactions |
ISO |
BDNF protein results in increased chemical synthesis of Nitric Oxide 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:17172126 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage |
ISO |
Nitric Oxide results in increased cleavage of BID protein |
CTD |
PMID:15126337 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of BIRC2 protein |
CTD |
PMID:14634119 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression decreases expression |
ISO |
Nitric Oxide results in increased expression of BIRC3 protein Nitric Oxide results in decreased expression of BIRC3 mRNA |
CTD |
PMID:14634119 PMID:15126337 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of BIRC5 mRNA Nitric Oxide results in decreased expression of BIRC5 protein |
CTD |
PMID:15126337 PMID:16166326 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of BMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression decreases expression |
EXP ISO |
Nitric Oxide results in increased expression of BNIP3 protein Nitric Oxide results in decreased expression of BNIP3 mRNA |
CTD |
PMID:11592958 PMID:16002567 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
EXP |
CACNA1A protein affects the reaction [Potassium Chloride results in increased abundance of Nitric Oxide] |
CTD |
PMID:12770949 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
multiple interactions |
EXP |
CACNA1B protein affects the reaction [Potassium Chloride results in increased abundance of Nitric Oxide] |
CTD |
PMID:12770949 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Calcrl |
calcitonin receptor like receptor |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of CALCRL mRNA; Nitric Oxide deficiency results in increased expression of CALCRL protein |
CTD |
PMID:16326922 |
|
NCBI chr 3:69,428,348...69,525,910
Ensembl chr 3:69,430,120...69,525,910
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
EXP |
[Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:17098364 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased activity of and results in increased cleavage of CASP1 protein |
CTD |
PMID:10903723 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases metabolic processing decreases activity decreases cleavage |
ISO EXP |
[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of CASP3 protein]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein]; Dithiothreitol inhibits the reaction [Nitric Oxide results in decreased activity of CASP3 protein]; Nitric Oxide inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein] Nitric Oxide results in increased activity of CASP3 protein Nitric Oxide results in increased metabolism of CASP3 protein [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; Cyclic GMP affects the reaction [Nitric Oxide results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one inhibits the reaction [[Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]]; Nitric Oxide affects the activity of and affects the cleavage of CASP3 protein; Nitric Oxide results in decreased cleavage of and results in decreased activity of CASP3 protein [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein] Nitric Oxide results in decreased cleavage of CASP3 protein |
CTD |
PMID:9388267 PMID:9706149 PMID:9755104 PMID:10222263 PMID:10358093 PMID:10728388 PMID:10811113 PMID:10828028 PMID:12606818 PMID:14634119 PMID:15126337 PMID:20020783 PMID:20179380 PMID:22878015 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
decreases cleavage |
ISO |
Nitric Oxide results in decreased cleavage of CASP7 protein |
CTD |
PMID:10222263 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
EXP ISO |
Nitric Oxide results in decreased cleavage of and results in decreased activity of CASP8 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP8 protein Nitric Oxide results in increased activity of CASP8 protein |
CTD |
PMID:10358093 PMID:15126337 PMID:22878015 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases activity multiple interactions increases activity |
ISO |
Nitric Oxide results in decreased activity of CASP9 protein [Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP9 protein Nitric Oxide results in increased activity of CASP9 protein |
CTD |
PMID:14634119 PMID:15126337 PMID:22878015 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of CAT mRNA]; Nitric Oxide promotes the reaction [Sertraline inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]]; Nitric Oxide promotes the reaction [Venlafaxine Hydrochloride inhibits the reaction [3-nitropropionic acid results in decreased activity of CAT protein]] |
CTD |
PMID:20305041 PMID:21983654 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions increases expression |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide; Nitric Oxide results in decreased ubiquitination of and results in decreased degradation of CAV1 protein; Nitric Oxide results in increased metabolism of and results in increased stability of CAV1 protein Nitric Oxide results in increased expression of CAV1 protein |
CTD |
PMID:18296501 PMID:19706615 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases secretion multiple interactions |
ISO |
Nitric Oxide results in decreased secretion of CCL5 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; [CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide; Disulfiram inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:13678430 PMID:19016906 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein |
CTD |
PMID:24412304 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; [CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide; Disulfiram inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [[CCL5 protein binds to and results in increased activity of CCR5 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:19016906 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
EXP |
CD14 protein affects the reaction [G(M1) Ganglioside results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [ganglioside, GD1a results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [Gangliosides results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; CD14 protein affects the reaction [trisialoganglioside GT1 results in increased secretion of Nitric Oxide] |
CTD |
PMID:16651628 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions increases abundance |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 5-diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:14607919 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of CD86 protein |
CTD |
PMID:13678430 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of CDH1 mRNA |
CTD |
PMID:20179380 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases chemical synthesis |
ISO |
CDX2 gene mutant form results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:29439001 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]] |
CTD |
PMID:12612912 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
EXP |
[(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to CHRM1 protein] which results in increased abundance of Nitric Oxide; [muscarinic toxin 7 binds to and results in decreased activity of CHRM1 protein] inhibits the reaction [Amphetamine results in increased abundance of Nitric Oxide] |
CTD |
PMID:18991861 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO EXP |
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; CNR1 protein affects the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in decreased abundance of Nitric Oxide]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in decreased abundance of Nitric Oxide] |
CTD |
PMID:10027878 PMID:11727767 PMID:11891798 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions increases expression |
EXP |
Amlodipine inhibits the reaction [Nitric Oxide deficiency results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10445667 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of COL5A3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of COX4I1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cpd |
carboxypeptidase D |
affects chemical synthesis multiple interactions |
ISO |
CPD affects the chemical synthesis of Nitric Oxide [PRL results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide; [Testosterone results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:21688280 |
|
NCBI chr10:61,623,528...61,687,491
Ensembl chr10:61,623,526...61,687,491
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
affects abundance |
ISO |
CPS1 gene SNP affects the abundance of Nitric Oxide metabolite |
CTD |
PMID:14718356 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions increases expression |
EXP |
CRH protein affects the reaction [Nitric Oxide results in increased secretion of POMC protein alternative form] Nitric Oxide results in increased expression of CRH mRNA |
CTD |
PMID:10460269 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
increases expression |
EXP |
Nitric Oxide results in increased expression of CRHR1 mRNA |
CTD |
PMID:10460269 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [BCAR1 protein binds to CRK protein] |
CTD |
PMID:12714323 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions decreases activity |
ISO |
[CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; [Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; CSF1 protein promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]; Enzyme Inhibitors inhibits the reaction [CSF1 protein promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide]]; Enzyme Inhibitors inhibits the reaction [Nitric Oxide results in decreased activity of CSF1 protein] [Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:8193360 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; Benzene promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; quinone promotes the reaction [[CSF1R protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7884313 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
EXP ISO |
[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide; CSF2 protein promotes the reaction [ITGB2 protein results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide] [CSF1 protein co-treated with CSF2 protein] promotes the reaction [Lipopolysaccharides results in increased chemical synthesis of Nitric Oxide] [Benzene co-treated with Enzyme Inhibitors] promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; [CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; hydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; hydroxyhydroquinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; quinone promotes the reaction [[CSF2 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7884313 PMID:8193360 PMID:8600936 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctf1 |
cardiotrophin 1 |
increases chemical synthesis |
EXP |
CTF1 protein results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:11304496 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of CTH mRNA |
CTD |
PMID:14508194 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctsd |
cathepsin D |
increases secretion |
EXP |
Nitric Oxide results in increased secretion of CTSD protein |
CTD |
PMID:15040013 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases secretion |
ISO |
Nitric Oxide results in decreased secretion of CXCL10 protein |
CTD |
PMID:13678430 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of CXCL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of CXCR4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
decreases secretion affects localization |
ISO EXP |
Nitric Oxide results in decreased secretion of CYCS protein Nitric Oxide affects the localization of CYCS protein |
CTD |
PMID:10222263 PMID:10356289 PMID:10358093 PMID:16024610 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[CYP2E1 protein results in increased metabolism of Ethanol] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18845238 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dab1 |
DAB adaptor protein 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of DAB1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552
|
|
G |
Ddah2 |
DDAH family member 2, ADMA-independent |
multiple interactions |
ISO |
DDAH2 promotes the reaction [tetramethylpyrazine inhibits the reaction [Iron-Dextran Complex results in decreased abundance of Nitric Oxide]] |
CTD |
PMID:32135237 |
|
NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511
|
|
G |
Ddc |
dopa decarboxylase |
increases activity |
EXP |
Nitric Oxide deficiency results in increased activity of DDC protein |
CTD |
PMID:7541690 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
increases activity |
EXP |
Nitric Oxide results in increased activity of DFFB protein |
CTD |
PMID:15040013 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization |
ISO |
Nitric Oxide affects the localization of DIABLO protein |
CTD |
PMID:15126337 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of DUSP1 mRNA |
CTD |
PMID:9699677 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of ECH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Edn1 |
endothelin 1 |
increases chemical synthesis increases expression increases secretion decreases activity increases abundance multiple interactions decreases expression |
ISO EXP |
EDN1 protein results in increased chemical synthesis of Nitric Oxide Nitric Oxide results in increased expression of EDN1 mRNA Nitric Oxide results in increased secretion of EDN1 protein Nitric Oxide deficiency results in increased expression of EDN1 mRNA Nitric Oxide deficiency results in decreased activity of EDN1 protein EDN1 protein results in increased abundance of Nitric Oxide [EDN1 protein results in increased activity of EDNRB protein] which results in increased abundance of Nitric Oxide; [EDN1 protein results in increased activity of NOS1 protein] which results in increased abundance of Nitric Oxide; BQ 788 inhibits the reaction [EDN1 protein results in increased abundance of Nitric Oxide]; Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]; S-methylthiocitrulline inhibits the reaction [EDN1 protein results in increased abundance of Nitric Oxide] Nitric Oxide results in increased expression of EDN1 protein Nitric Oxide results in decreased expression of EDN1 protein |
CTD |
PMID:11187978 PMID:15640287 PMID:15838368 PMID:16326922 PMID:16380457 PMID:16389725 PMID:16810074 PMID:20197249 PMID:20929026 More...
|
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
[EDN1 protein results in increased activity of EDNRB protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:16380457 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of EEF1A1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of EEF1B2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:64,580,163...64,582,737
Ensembl chr 9:64,579,893...64,582,737
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of EHMT2 protein |
CTD |
PMID:23546878 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of EIF1A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:39,325,695...39,338,043
Ensembl chr18:39,325,202...39,338,696
|
|
G |
Eif2ak1 |
eukaryotic translation initiation factor 2 alpha kinase 1 |
multiple interactions |
ISO |
Nitric Oxide inhibits the reaction [Mercury results in decreased activity of EIF2AK1 protein] |
CTD |
PMID:17689536 |
|
NCBI chr12:10,710,771...10,744,597
Ensembl chr12:10,705,874...10,744,573
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B subunit delta |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of EIF2B4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:25,183,177...25,188,832
Ensembl chr 6:25,183,186...25,188,829
|
|
G |
Eif3g |
eukaryotic translation initiation factor 3, subunit G |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of EIF3G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:19,429,728...19,433,760
Ensembl chr 8:19,429,643...19,433,808
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
EPAS1 protein affects the reaction [Cobalt results in increased abundance of Nitric Oxide]; EPAS1 protein affects the reaction [Nickel results in increased abundance of Nitric Oxide] |
CTD |
PMID:23788631 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
EXP |
EPO protein results in decreased susceptibility to Nitric Oxide |
CTD |
PMID:15816862 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18296501 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of EZH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Ezr |
ezrin |
increases phosphorylation |
EXP |
Nitric Oxide deficiency results in increased phosphorylation of EZR protein |
CTD |
PMID:14732730 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions increases abundance |
ISO |
arsenite inhibits the reaction [F2 protein results in increased abundance of Nitric Oxide]; F2 protein promotes the reaction [Heparin results in increased abundance of Nitric Oxide] |
CTD |
PMID:8408661 PMID:22244921 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Nitric Oxide results in increased expression of FAS mRNA; Nitric Oxide results in increased expression of FAS protein |
CTD |
PMID:15126337 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [linsidomine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [Etoposide results in increased activity of FASLG promoter]; [spermine nitric oxide complex results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine results in increased activity of FASLG promoter]; Nitric Oxide inhibits the reaction [Etoposide results in increased activity of FASLG promoter] |
CTD |
PMID:10811113 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases abundance multiple interactions |
EXP |
FGF1 protein results in increased abundance of Nitric Oxide PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:16524372 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases activity |
EXP |
Nitric Oxide results in increased activity of FOSB protein |
CTD |
PMID:15949472 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Ftl1 |
ferritin light chain 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of FTL1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions increases expression |
EXP ISO |
[7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat affects the localization of GAPDH protein] Nitric Oxide deficiency results in increased expression of GAPDH mRNA |
CTD |
PMID:15878706 PMID:20478973 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gata5 |
GATA binding protein 5 |
multiple interactions increases expression increases response to substance |
EXP |
GATA5 protein promotes the reaction [Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2L1 mRNA]]; GATA5 protein promotes the reaction [Nitric Oxide results in increased expression of BCL2L1 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 mRNA]; Nitric Oxide inhibits the reaction [Hydrogen Peroxide results in decreased expression of GATA5 protein] Nitric Oxide results in increased expression of GATA5 mRNA; Nitric Oxide results in increased expression of GATA5 protein GATA5 protein results in increased susceptibility to Nitric Oxide |
CTD |
PMID:25726415 |
|
NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of GCLC mRNA; Nitric Oxide deficiency results in decreased expression of GCLC protein |
CTD |
PMID:19631198 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
GCLM gene SNP affects the abundance of and affects the activity of and affects the susceptibility to Nitric Oxide |
CTD |
PMID:12975258 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of GDI2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of GFAP protein |
CTD |
PMID:15763998 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of GJA1 mRNA; Nitric Oxide deficiency results in decreased expression of GJA1 protein; Nitric Oxide results in decreased expression of GJA1 protein |
CTD |
PMID:10397678 PMID:11856964 PMID:20004189 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glb1 |
galactosidase, beta 1 |
decreases activity |
ISO |
Nitric Oxide results in decreased activity of GLB1 protein |
CTD |
PMID:17075048 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gltp |
glycolipid transfer protein |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GLTP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:41,907,168...41,927,321
Ensembl chr12:41,907,144...41,927,319
|
|
G |
Gpc1 |
glypican 1 |
increases nitrosation multiple interactions |
ISO |
Nitric Oxide results in increased nitrosation of GPC1 protein [Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form; Zinc promotes the reaction [[Ascorbic Acid co-treated with Nitric Oxide] results in increased degradation of GPC1 protein modified form] |
CTD |
PMID:15677459 PMID:16923158 |
|
NCBI chr 9:93,396,234...93,424,047
Ensembl chr 9:93,396,234...93,424,047
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GPI1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects metabolic processing multiple interactions |
ISO |
GPX1 protein affects the metabolism of Nitric Oxide GPX1 protein affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide] |
CTD |
PMID:11498278 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GPX2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression multiple interactions |
ISO EXP |
Nitric Oxide deficiency results in increased expression of GPX3 mRNA Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of GPX3 mRNA] |
CTD |
PMID:15878706 PMID:21983654 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of GRB2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gsn |
gelsolin |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GSN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions affects activity |
EXP |
Nitric Oxide deficiency results in increased expression of GSR protein tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of GSR protein] Nitric Oxide deficiency affects the activity of GSR protein |
CTD |
PMID:15925750 PMID:19631198 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GSTM1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of GSTM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions increases response to substance |
ISO |
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]] GUCY1A1 gene mutant form results in increased susceptibility to Nitric Oxide |
CTD |
PMID:11744065 PMID:25373139 |
|
NCBI chr 2:167,418,615...167,482,293
Ensembl chr 2:167,418,640...167,481,671
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole affects the folding of [Nitric Oxide binds to [GUCY1A1 protein binds to GUCY1B1 protein]] |
CTD |
PMID:11744065 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of HADH mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of HAVCR1 protein |
CTD |
PMID:19834340 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hbs1l |
HBS1-like translational GTPase |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of HBS1L mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:16,092,529...16,170,082
Ensembl chr 1:16,092,547...16,170,074
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases abundance |
EXP |
HCRT results in increased abundance of Nitric Oxide |
CTD |
PMID:18378017 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Nitric Oxide results in decreased stability of and results in decreased expression of HIF1A protein; U 0126 inhibits the reaction [Nitric Oxide results in decreased degradation of and results in increased activity of HIF1A protein] |
CTD |
PMID:16310922 PMID:18424783 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases response to substance increases expression affects activity multiple interactions affects response to substance |
EXP ISO |
HMOX1 protein results in decreased susceptibility to Nitric Oxide Nitric Oxide results in increased expression of HMOX1 protein Nitric Oxide affects the activity of HMOX1 protein Nitric Oxide results in increased expression of HMOX1 mRNA; Nitric Oxide results in increased expression of HMOX1 protein HMOX1 protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide]; Nitric Oxide results in increased stability of and results in increased expression of HMOX1 mRNA HMOX1 protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:9699677 PMID:15220209 PMID:17020887 PMID:17401437 PMID:18178725 PMID:19183270 PMID:20888885 PMID:21690482 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis |
ISO |
Nitric Oxide results in increased mutagenesis of HPRT1 gene |
CTD |
PMID:22303861 PMID:28454271 |
|
NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 protein |
CTD |
PMID:19320461 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
EXP |
[sodium arsenite results in increased expression of HSPA8 protein] which results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:10216529 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hyal2 |
hyaluronidase 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of HYAL2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:108,241,895...108,246,853
Ensembl chr 8:108,243,133...108,246,850
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of ICAM1 protein]] |
CTD |
PMID:14762100 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
Nitric Oxide binds to and affects the folding of and results in increased degradation of and results in decreased activity of IDO1 protein |
CTD |
PMID:16834326 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; Dexamethasone inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; tocotrienol, delta inhibits the reaction [[IFNB1 protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide] |
CTD |
PMID:22185406 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
increases secretion increases chemical synthesis multiple interactions increases abundance |
ISO EXP |
Nitric Oxide results in increased secretion of IFNG protein IFNG protein results in increased chemical synthesis of Nitric Oxide 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; 5-nitro-2-(3-phenylpropylamino)benzoic acid inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides co-treated with quinone] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lead acetate results in increased abundance of Lead] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased secretion of Nitric Oxide; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Aminosalicylic Acids inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; aristolochic acid I inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF2 protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Benzene promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; Capsaicin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Capsaicin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; capsazepine inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; catalpol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; chromous chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltiprotoporphyrin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cupric chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Dexamethasone inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Dexamethasone inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Diquat promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; Dronabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased abundance of Nitric Oxide]; Estriol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Glyburide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; GPX1 protein affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; GW 1929 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Ibuprofen inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; IFNG promotes the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; IFNG protein inhibits the reaction [Cyclophosphamide results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with Benzene] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with hydroquinone] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [[Lipopolysaccharides co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide]; IFNG protein promotes the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Indomethacin inhibits the reaction [[APP protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; JAK2 protein promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Lipopolysaccharides promotes the reaction [[IFNG protein co-treated with hydroxyhydroquinone] results in increased abundance of Nitric Oxide]; Lipopolysaccharides promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; MK 473 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NS 1652 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; NS-3728 inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased metabolism of Nitric Oxide]; pimagedine inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; pimagedine inhibits the reaction [Lipopolysaccharides promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; resiniferatoxin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; resiniferatoxin inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Sulfasalazine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Tamoxifen inhibits the reaction [IFNG protein results in increased metabolism of Nitric Oxide]; TBE 31 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; tocotrienol, delta inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; U 0126 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; zinc chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]] [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Benzene promotes the reaction [[[Lipopolysaccharides co-treated with IFNG protein] co-treated with CSF1 protein] results in increased chemical synthesis of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Clofibrate inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; CSF1 protein promotes the reaction [IFNG protein results in increased chemical synthesis of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; Ditiocarb inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; Gemfibrozil inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; morin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of Nitric Oxide]; pterostilbene inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] IFNG protein results in increased abundance of Nitric Oxide; IFNG results in increased abundance of Nitric Oxide (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; [IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with Manganese] results in decreased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [pyrazolanthrone co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [SB 203580 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [U 0126 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Apigenin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Cannabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Deoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; IFNG promotes the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; Indomethacin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Manganese inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Nitric Oxide affects the susceptibility to [IFNG protein co-treated with Lipopolysaccharides]; Ozone promotes the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; Polyphenols inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [IFNG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]]; Rimonabant inhibits the reaction [Cannabinol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; S-methylisothiopseudouronium inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; U 0126 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ursodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:7519435 PMID:7689037 PMID:7884313 PMID:8193360 PMID:8341679 PMID:8765472 PMID:8903404 PMID:8975779 PMID:8979148 PMID:10205001 PMID:10607705 PMID:10909967 PMID:11020457 PMID:11063824 PMID:11080519 PMID:11282106 PMID:11498278 PMID:11520904 PMID:11529938 PMID:11727767 PMID:11907163 PMID:12244038 PMID:12612912 PMID:12620498 PMID:12847270 PMID:12911628 PMID:13678430 PMID:14530214 PMID:14617770 PMID:14623498 PMID:15177305 PMID:16168523 PMID:16307444 PMID:16366677 PMID:16488514 PMID:16968468 PMID:18090225 PMID:18206661 PMID:19393675 PMID:19446535 PMID:19825429 PMID:20424383 PMID:21361338 PMID:21943492 PMID:22185406 PMID:22461696 PMID:22698256 PMID:23164921 PMID:23362215 PMID:24412304 PMID:25766886 PMID:28242320 PMID:34352350 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
decreases secretion |
ISO |
Nitric Oxide results in decreased secretion of IL10 protein |
CTD |
PMID:13678430 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of IL12B protein |
CTD |
PMID:13678430 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of IL12RB2 mRNA |
CTD |
PMID:12451176 |
|
NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions increases abundance |
ISO EXP |
[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:16968468 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases chemical synthesis increases abundance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with Fatty Acids, Nonesterified] results in increased chemical synthesis of Nitric Oxide; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; bisphenol A inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Clofibrate inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; cordycepin inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Cytochalasin B inhibits the reaction [Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; Cytochalasin B inhibits the reaction [Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; Dactinomycin inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; Estradiol inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Gemfibrozil inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Glucosamine analog affects the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Nitric Oxide]; Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; IL1B protein promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; IL4 protein inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Leflunomide inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; LEP protein affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Methotrexate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of ICAM1 protein]]; Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of SELE protein]]; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; pimagedine inhibits the reaction [Asbestos, Crocidolite promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; pimagedine inhibits the reaction [Asbestos, Serpentine promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]]; sauchinone inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Triglycerides affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Troglitazone inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Troglitazone inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide] [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; IL1B protein promotes the reaction [Cobalt results in increased abundance of Nitric Oxide]; IL1B protein promotes the reaction [Nickel results in increased abundance of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA] IL1B protein results in increased abundance of Nitric Oxide; IL1B results in increased abundance of Nitric Oxide [Enzyme Inhibitors results in decreased abundance of Nitric Oxide] inhibits the reaction [IL1B protein results in decreased secretion of INS1 protein]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; Active Hexose Correlated Compound inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Active Hexose Correlated Compound inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Apigenin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; IL1B protein affects the reaction [AVP protein affects the metabolism of Nitric Oxide]; Luteolin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SOD2 protein inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; Vitamin E inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:7519435 PMID:8903404 PMID:8982730 PMID:9312173 PMID:9576743 PMID:9698594 PMID:10365824 PMID:10909967 PMID:11229466 PMID:11286988 PMID:11457450 PMID:11530235 PMID:12115740 PMID:12244038 PMID:12384474 PMID:14617770 PMID:14623498 PMID:14762100 PMID:14996425 PMID:15144122 PMID:15223066 PMID:16393772 PMID:16492401 PMID:17109745 PMID:17712145 PMID:18026701 PMID:18078833 PMID:18090225 PMID:19347386 PMID:19393675 PMID:20600708 PMID:21171372 PMID:21943492 PMID:23788631 PMID:24346509 PMID:24425765 PMID:24878381 PMID:25766886 PMID:29356224 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
IL4 protein inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide] IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:12115740 PMID:12612912 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions decreases secretion |
ISO |
[IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide Nitric Oxide results in decreased secretion of IL5 protein |
CTD |
PMID:13678430 PMID:18206661 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of IL6 protein] which results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of IL6 protein] |
CTD |
PMID:20708382 PMID:21983654 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
[Enzyme Inhibitors results in decreased abundance of Nitric Oxide] inhibits the reaction [IL1B protein results in decreased secretion of INS1 protein] |
CTD |
PMID:24425765 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
increases secretion decreases secretion multiple interactions increases chemical synthesis |
ISO |
INS protein results in increased secretion of Nitric Oxide INS protein results in decreased secretion of Nitric Oxide [INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide; [Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]; Kynurenic Acid inhibits the reaction [[INS protein co-treated with Glucose] results in decreased chemical synthesis of Nitric Oxide]; Orotic Acid inhibits the reaction [INS protein results in increased abundance of Nitric Oxide]; Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]; PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide]; quercetin 3-O-glucuronide inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]]; Quercetin inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]]; resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]; SIRT1 protein affects the reaction [INS protein results in increased secretion of Nitric Oxide]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]]; Sodium Salicylate inhibits the reaction [Palmitates inhibits the reaction [INS protein results in increased chemical synthesis of Nitric Oxide]] |
CTD |
PMID:20960276 PMID:23504962 PMID:25601987 PMID:26364587 PMID:28951307 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Itga6 |
integrin subunit alpha 6 |
multiple interactions decreases abundance |
EXP |
AG 1879 inhibits the reaction [ITGA6 protein results in decreased abundance of Nitric Oxide] |
CTD |
PMID:36731809 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions increases abundance |
ISO EXP |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP1A protein]; Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP2A protein] ITGB2 protein results in increased abundance of Nitric Oxide [CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide; [ITGB2 protein results in increased susceptibility to Ozone] which results in increased abundance of Nitric Oxide; CSF2 protein promotes the reaction [ITGB2 protein results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[CSF2 protein results in increased expression of ITGB2 protein] which results in increased abundance of Nitric Oxide] |
CTD |
PMID:8600936 PMID:16963453 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
ISO |
Nitric Oxide results in increased expression of ITGB3 protein |
CTD |
PMID:21332719 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jak1 |
Janus kinase 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of JAK1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression |
ISO |
JAK2 protein promotes the reaction [IFNG protein results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of JAK2 mRNA |
CTD |
PMID:12847270 PMID:15878706 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases activity |
EXP |
Nitric Oxide results in increased activity of JUN protein |
CTD |
PMID:15949472 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases activity |
EXP |
Nitric Oxide results in increased activity of JUNB protein |
CTD |
PMID:15949472 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM1A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm3a |
lysine demethylase 3A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM3A mRNA; Nitric Oxide results in increased expression of KDM3A protein |
CTD |
PMID:23546878 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Kdm3b |
lysine demethylase 3B |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM3B mRNA |
CTD |
PMID:23546878 |
|
NCBI chr18:26,380,859...26,436,701
Ensembl chr18:26,380,964...26,436,628
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Kdm4b |
lysine demethylase 4B |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4B mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543
|
|
G |
Kdm4c |
lysine demethylase 4C |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4C mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 5:88,100,710...88,306,821
Ensembl chr 5:88,100,733...88,306,818
|
|
G |
Kdm4d |
lysine demethylase 4D |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM4D mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 8:11,279,756...11,304,920
Ensembl chr 8:11,268,859...11,305,290
|
|
G |
Kdm7a |
lysine demethylase 7A |
increases expression |
ISO |
Nitric Oxide results in increased expression of KDM7A mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998
|
|
G |
Klk1 |
kallikrein 1 |
multiple interactions increases abundance |
EXP |
icatibant inhibits the reaction [KLK1 protein results in increased abundance of Nitric Oxide]; KLK1 protein inhibits the reaction [Gentamicins results in decreased abundance of Nitric Oxide] |
CTD |
PMID:16401625 |
|
NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754
|
|
G |
Kng1 |
kininogen 1 |
increases secretion multiple interactions increases abundance affects abundance |
EXP ISO |
KNG1 protein results in increased secretion of Nitric Oxide PD 123319 affects the reaction [KNG1 affects the abundance of Nitric Oxide] KNG1 protein results in increased abundance of Nitric Oxide [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased chemical synthesis of Nitric Oxide; Lipopolysaccharides promotes the reaction [KNG1 protein modified form results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:10535458 PMID:16514058 PMID:16733097 PMID:29775649 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
LEP protein affects the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:9312173 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
LIF protein affects the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased abundance of Nitric Oxide]]; LIF protein inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased abundance of Nitric Oxide] |
CTD |
PMID:23409146 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Ltf |
lactotransferrin |
increases chemical synthesis decreases activity |
EXP |
LTF protein results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in decreased activity of LTF protein |
CTD |
PMID:14563657 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation decreases expression |
EXP |
Nitric Oxide affects the reaction [Ditiocarb results in increased phosphorylation of MAPK1 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK1 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein] Nitric Oxide results in decreased phosphorylation of MAPK1 protein Nitric Oxide results in decreased expression of MAPK1 protein |
CTD |
PMID:14713289 PMID:15640287 PMID:16389725 PMID:16575906 PMID:16603213 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation decreases expression |
EXP |
Nitric Oxide affects the reaction [Ditiocarb results in increased phosphorylation of MAPK3 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK3 protein]; Nitric Oxide inhibits the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein] Nitric Oxide results in decreased phosphorylation of MAPK3 protein Nitric Oxide results in decreased expression of MAPK3 protein |
CTD |
PMID:14713289 PMID:15640287 PMID:16389725 PMID:16575906 PMID:16603213 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
increases abundance multiple interactions |
EXP |
MBP protein results in increased abundance of Nitric Oxide Testosterone inhibits the reaction [MBP protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:18579221 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of MEF2A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
[1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; [S-nitrosocysteine results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein; Dithiothreitol inhibits the reaction [[1-hydroxy-2-oxo-3-(3-aminopropyl)-3-isopropyl-1-triazene results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein]; Dithiothreitol inhibits the reaction [[S-nitrosocysteine results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein]; Dithiothreitol inhibits the reaction [[S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased activity of MGST1 protein] |
CTD |
PMID:16386761 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
EXP ISO |
Nitric Oxide results in decreased expression of MMP2 protein Nitric Oxide results in increased expression of and results in increased activity of MMP2 protein |
CTD |
PMID:16575906 PMID:18796497 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
Nitric Oxide results in increased expression of MMP9 mRNA |
CTD |
PMID:20197249 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
increases expression multiple interactions increases oxidation |
EXP ISO |
Nitric Oxide results in increased expression of MPO protein 4-amino-TEMPO inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [1,6-diaminohexane binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Cadaverine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [ethylenediamine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Putrescine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [Spermine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide]; [trimethylenediamine binds to TEMPO] inhibits the reaction [MPO protein results in increased oxidation of Nitric Oxide] [Paraquat co-treated with Nitric Oxide] results in increased activity of MPO protein |
CTD |
PMID:10706834 PMID:15820443 PMID:34085520 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of MRPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:100,843,691...100,846,838
Ensembl chr10:100,843,356...100,847,129
|
|
G |
Msn |
moesin |
increases phosphorylation |
EXP |
Nitric Oxide deficiency results in increased phosphorylation of MSN protein |
CTD |
PMID:14732730 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
affects activity affects expression |
EXP |
Nitric Oxide affects the activity of COX1 protein Nitric Oxide affects the expression of COX1 mRNA |
CTD |
PMID:17936468 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
Nitric Oxide binds to and results in decreased activity of MT1A protein Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA] |
CTD |
PMID:10548558 PMID:14617770 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA] |
CTD |
PMID:14617770 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
EXP |
MT3 protein results in decreased susceptibility to Nitric Oxide |
CTD |
PMID:10854270 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]] |
CTD |
PMID:22363816 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of MYH6 mRNA |
CTD |
PMID:16326922 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression multiple interactions |
EXP |
Nitric Oxide deficiency results in increased expression of MYH7 mRNA Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA] |
CTD |
PMID:16326922 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ndn |
necdin, MAGE family member |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of NDN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:115,849,168...115,850,767
Ensembl chr 1:115,849,105...115,850,767
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of NDRG1 mRNA; Nitric Oxide results in increased expression of NDRG1 protein |
CTD |
PMID:21976667 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of NDUFA13 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
NFKB1 protein promotes the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:12162464 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]] |
CTD |
PMID:16168523 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK1 protein]; Nitric Oxide affects the reaction [NGF protein results in increased activity of MAPK3 protein] |
CTD |
PMID:14713289 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions increases chemical synthesis decreases expression |
ISO EXP |
7-nitroindazole inhibits the reaction [[N-isopropylbenzylamine results in increased expression of NOS1 protein] which results in increased abundance of Nitric Oxide]; [N-isopropylbenzylamine results in increased expression of NOS1 protein] which results in increased abundance of Nitric Oxide; PLAT protein affects the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of NOS1 protein [Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide]; [Cisplatin results in increased expression of NOS1 mRNA] which results in increased abundance of Nitric Oxide; [EDN1 protein results in increased activity of NOS1 protein] which results in increased abundance of Nitric Oxide; [Formaldehyde results in increased expression of NOS1 protein] which results in increased abundance of Nitric Oxide; [NOS1 protein results in increased reduction of Trinitrotoluene] which results in decreased chemical synthesis of Nitric Oxide |
CTD |
PMID:15223068 PMID:15249212 PMID:16380457 PMID:17098364 PMID:18195371 PMID:19038279 PMID:23359814 PMID:24184442 PMID:25766886 PMID:36162621 More...
|
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases abundance affects abundance multiple interactions increases chemical synthesis decreases expression affects expression increases expression |
ISO EXP |
NOS2 protein results in increased abundance of Nitric Oxide NOS2 promoter polymorphism affects the abundance of Nitric Oxide 1,2-naphthoquinone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; [3,5-dimethoxy-4'-hydroxystilbene results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]] which results in decreased abundance of Nitric Oxide; [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of CCN2 protein; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA; [Acetaminophen results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Aspirin results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Benzene promotes the reaction [[CSF1 protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]] which results in increased chemical synthesis of Nitric Oxide; [Cisplatin results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [cobaltous chloride results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Deferoxamine results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide; [diferuloylputrescine results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [ferulic acid results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein; [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide; [Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Nicotine results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased expression of TJP1 mRNA; [Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [p-coumaric acid results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [pimobendan results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Plant Extracts results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [prunetin results in decreased expression of NOS2 mRNA] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased chemical synthesis of Nitric Oxide]; [Putrescine metabolite results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Quercetin results in decreased expression of NOS2 mRNA] inhibits the reaction [Nitric Oxide results in increased expression of BCL2 mRNA]; [S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Selenium inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]] which results in decreased chemical synthesis of Nitric Oxide; [Sodium Salicylate results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Thiourea analog results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Zoledronic Acid results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; bepafant inhibits the reaction [[Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; bisphenol A inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Caffeine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Capsaicin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Capsaicin inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; capsazepine inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Carthamus yellow inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Chalcone analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2] which results in increased abundance of Nitric Oxide]; chromous chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; ciglitazone inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Cilostazol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cupric chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Cyclosporine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; diphenylmethyl selenocyanate inhibits the reaction [[Cisplatin results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Drugs, Chinese Herbal inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; ent-1,3,6,11-tetrahydroxykaur-16-ene-15-one 3,11-diacetate inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide]]; erythraline inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; ethyl N-allyl-N-(2-methyl-3-(4-(4-amidinophenoxycarbonyl)phenyl)propenoyl)aminoacetate methanesulfonate inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; flavokawain A inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Fluoxetine analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Ginkgo biloba extract inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; GW 1929 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; hinokiresinol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; lead chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; matairesinol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; naringenin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; NFKB1 protein promotes the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; nimesulide inhibits the reaction [bepafant inhibits the reaction [[Mycoplasma arthritidis mitogen results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]]; Nitroprusside inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein results in increased chemical synthesis of and results in increased abundance of Nitric Oxide; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; praeruptorin A inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Pyrazines inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Quercetin analog inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Quercetin inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Quercetin inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; quercetin pentaacetate inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; resiniferatoxin inhibits the reaction [[IFNG protein results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; resiniferatoxin inhibits the reaction [[Lipopolysaccharides results in increased abundance of Nitric Oxide] which results in increased expression of NOS2 protein]; Resveratrol inhibits the reaction [[[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Resveratrol metabolite inhibits the reaction [Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Rutin inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; STAT1 protein promotes the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; timosaponin BIII inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; zinc chloride inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]] Nitric Oxide deficiency results in decreased expression of NOS2 protein Nitric Oxide deficiency affects the expression of NOS2 protein [Endotoxins results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Ethanol results in decreased expression of and results in decreased activity of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Formaldehyde results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Fructose results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Gentamicins results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Indomethacin results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Isoproterenol results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased susceptibility to endothelium-dependent hyperpolarization factor; [notoginsenoside R1 results in increased phosphorylation of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; Active Hexose Correlated Compound inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Edaravone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Endotoxins inhibits the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Lipopolysaccharides promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; natakalim inhibits the reaction [[Isoproterenol results in increased expression of NOS2] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of NOS2 mRNA]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Ozone promotes the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Ozone results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Resveratrol inhibits the reaction [[Taurocholic Acid results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; wuzi yanzong analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] [[Fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [[Particulate Matter results in increased abundance of Ammonium Compounds] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [[Particulate Matter results in increased abundance of Carbon] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [[Particulate Matter results in increased abundance of Nitrates] which results in decreased methylation of NOS2 promoter] which results in increased abundance of Nitric Oxide; [Acetaldehyde results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Ethanol results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [Fluvastatin results in increased abundance of Nitric Oxide]; [Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; [NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein; [Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide; [Resveratrol results in decreased expression of NOS2 protein] which results in decreased abundance of Nitric Oxide; [Tobacco Smoke Pollution results in increased expression of and results in increased activity of NOS2 protein] which results in increased abundance of Nitric Oxide; [Trichloroethylene results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [Vehicle Emissions results in increased abundance of Air Pollutants] inhibits the reaction [NOS2 promoter polymorphism affects the abundance of Nitric Oxide]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Cyclosporine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in decreased activity of CASP3 protein]; Dithiothreitol inhibits the reaction [[NOS2 protein results in increased abundance of Nitric Oxide] which results in increased metabolism of CASP3 protein]; Gold Sodium Thiomalate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; HMOX1 protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide]; Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; IL1B protein promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; Leflunomide inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; lornoxicam inhibits the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Methotrexate inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nicotine promotes the reaction [NOS2 protein results in increased abundance of Nitric Oxide]; Peptides inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Tacrolimus inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; XDH protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide] Nitric Oxide results in increased expression of NOS2 mRNA; Nitric Oxide results in increased expression of NOS2 protein |
CTD |
PMID:7519435 PMID:7705308 PMID:8193360 PMID:8652180 PMID:8975779 PMID:8982730 PMID:9288130 PMID:9530173 PMID:9706149 PMID:9743513 PMID:9755104 PMID:9788894 PMID:10022268 PMID:10086329 PMID:10090849 PMID:10188978 PMID:10193745 PMID:10450786 PMID:10860828 PMID:10909967 PMID:11020457 PMID:11173986 PMID:11286988 PMID:11500931 PMID:11518563 PMID:11530235 PMID:11919077 PMID:12060119 PMID:12133974 PMID:12144947 PMID:12162464 PMID:12175900 PMID:12612912 PMID:12847270 PMID:12860292 PMID:14530214 PMID:15242784 PMID:15249212 PMID:15364003 PMID:15529353 PMID:16168523 PMID:16376947 PMID:16389574 PMID:16393772 PMID:16927020 PMID:16944022 PMID:17067557 PMID:17135264 PMID:17135361 PMID:17312373 PMID:17448908 PMID:17467989 PMID:17541474 PMID:17570326 PMID:17630198 PMID:17651055 PMID:17712145 PMID:17719164 PMID:18073202 PMID:18078833 PMID:18369347 PMID:18481332 PMID:18507870 PMID:18550010 PMID:18796497 PMID:18838107 PMID:18845238 PMID:19631198 PMID:19818098 PMID:20004183 PMID:20023007 PMID:20035746 PMID:20417174 PMID:20527891 PMID:20558268 PMID:20708382 PMID:20712904 PMID:20842678 PMID:20848677 PMID:20888885 PMID:20942565 PMID:20955790 PMID:21139339 PMID:21256160 PMID:21284090 PMID:21464294 PMID:21467642 PMID:21893401 PMID:21926162 PMID:21983654 PMID:22076046 PMID:22101131 PMID:22155221 PMID:22224493 PMID:22227475 PMID:22251620 PMID:22342441 PMID:22366099 PMID:22472292 PMID:22974838 PMID:23106696 PMID:23359814 PMID:23597450 PMID:23727179 PMID:23774260 PMID:23902980 PMID:24161485 PMID:24412304 PMID:24964743 PMID:25766886 PMID:25870319 PMID:26045775 PMID:26372312 PMID:26714306 PMID:27174236 PMID:28512713 PMID:30322157 PMID:36049621 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases chemical synthesis multiple interactions increases chemical synthesis affects chemical synthesis decreases expression affects expression increases abundance |
ISO EXP |
NOS3 gene mutant form results in decreased chemical synthesis of Nitric Oxide 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]]; [[resveratrol results in increased activity of PPARA protein] which results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Estradiol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [Glycochenodeoxycholic Acid results in decreased expression of NOS3 protein] which results in decreased abundance of Nitric Oxide; [Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide; [Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of RCN1 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of TXNDC5 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in decreased expression of HSPA5 protein; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 protein; [Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; [Orotic Acid inhibits the reaction [Metformin results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide; [puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [resveratrol results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [resveratrol results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide; [resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; [Trichloroethylene results in increased activity of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; Amiodarone promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; desethylamiodarone promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; fulvestrant inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; icariin promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; NOX5 protein promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide]; resveratrol inhibits the reaction [[Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide]; rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; SOD1 protein inhibits the reaction [Nitric Oxide results in decreased activity of NOS3 protein]; Stilbenes inhibits the reaction [[Hydrogen Peroxide results in decreased activity of NOS3 protein] which results in decreased chemical synthesis of Nitric Oxide]; Tretinoin promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; U 0126 inhibits the reaction [[resveratrol results in increased phosphorylation of and results in increased activity of NOS3 protein] which results in increased abundance of Nitric Oxide]; W 7 inhibits the reaction [[puerarin results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]; wortmannin inhibits the reaction [rosiglitazone inhibits the reaction [[Glucose results in decreased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide]] NOS3 protein affects the chemical synthesis of Nitric Oxide [Bezafibrate results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide; [GULO protein co-treated with NOS3 protein] results in increased abundance of Nitric Oxide; [Resveratrol results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide; dorsomorphin inhibits the reaction [[Bezafibrate results in increased phosphorylation of NOS3 protein] which results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in decreased expression of NOS3 mRNA; Nitric Oxide deficiency results in decreased expression of NOS3 protein Nitric Oxide deficiency affects the expression of NOS3 protein [Sildenafil Citrate results in increased expression of NOS3 protein] which results in increased secretion of Nitric Oxide; AGT protein alternative form promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide]; Enalapril inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of NOS3 mRNA]; Thioacetamide promotes the reaction [NOS3 protein results in increased chemical synthesis of Nitric Oxide] NOS3 protein results in increased abundance of Nitric Oxide |
CTD |
PMID:10445667 PMID:11740345 PMID:12270858 PMID:12489993 PMID:15207323 PMID:15249212 PMID:16043647 PMID:16197366 PMID:16479044 PMID:16737683 PMID:17499557 PMID:17719164 PMID:18296501 PMID:18556569 PMID:18716157 PMID:18990443 PMID:19011239 PMID:19320461 PMID:19631198 PMID:19696404 PMID:19767878 PMID:19845545 PMID:20020783 PMID:20562903 PMID:20675566 PMID:21499286 PMID:21791144 PMID:21884717 PMID:21983654 PMID:22314268 PMID:22358095 PMID:24184442 PMID:25601987 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of NPC1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPA mRNA] Nitric Oxide deficiency results in increased expression of NPPA mRNA; Nitric Oxide deficiency results in increased expression of NPPA protein |
CTD |
PMID:10397678 PMID:12198334 PMID:14700747 PMID:15177930 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions increases expression |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]; Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA] Nitric Oxide deficiency results in increased expression of NPPB mRNA; Nitric Oxide deficiency results in increased expression of NPPB protein |
CTD |
PMID:12198334 PMID:16326922 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of NR2F2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:17490654 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
EXP |
Nitric Oxide results in increased expression of NR4A1 mRNA |
CTD |
PMID:10460269 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of NUPR1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Ocln |
occludin |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of OCLN protein |
CTD |
PMID:15763998 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of P4HA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] inhibits the reaction [N-caproylsphingosine promotes the reaction [CASP3 protein results in increased cleavage of PARP1 protein]] PARP1 gene mutant form inhibits the reaction [S100B protein results in increased secretion of Nitric Oxide] Nitric Oxide results in increased cleavage of PARP1 protein |
CTD |
PMID:10811113 PMID:15126337 PMID:16024610 PMID:27444121 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdcd6ip |
programmed cell death 6 interacting protein |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PDCD6IP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773
|
|
G |
Pde5a |
phosphodiesterase 5A |
increases expression affects response to substance |
EXP |
Nitric Oxide results in increased expression of PDE5A mRNA; Nitric Oxide results in increased expression of PDE5A protein PDE5A protein affects the susceptibility to Nitric Oxide |
CTD |
PMID:19374906 |
|
NCBI chr 2:210,858,515...211,003,480
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Phf8 |
PHD finger protein 8 |
increases expression |
ISO |
Nitric Oxide results in increased expression of PHF8 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr X:20,524,103...20,623,459
Ensembl chr X:20,524,558...20,623,410
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions |
ISO |
PIK3CA protein inhibits the reaction [[Orotic Acid inhibits the reaction [INS protein results in increased phosphorylation of NOS3 protein]] which results in decreased abundance of Nitric Oxide] |
CTD |
PMID:25601987 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
EXP |
Nitric Oxide affects the reaction [Ditiocarb results in increased expression of PLA2G4A mRNA]; Nitric Oxide affects the reaction [Ditiocarb results in increased expression of PLA2G4A protein] |
CTD |
PMID:16603213 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions increases secretion |
ISO |
PLAT protein affects the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide] PLAT protein results in increased secretion of Nitric Oxide |
CTD |
PMID:18195371 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Nitric Oxide results in increased expression of PMAIP1 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of PMS2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:10,676,818...10,701,161
Ensembl chr12:10,676,764...10,701,066
|
|
G |
Pnoc |
prepronociceptin |
decreases activity |
EXP |
Nitric Oxide deficiency results in decreased activity of PNOC protein |
CTD |
PMID:10794074 |
|
NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions decreases abundance increases secretion |
EXP |
CRH protein affects the reaction [Nitric Oxide results in increased secretion of POMC protein alternative form] POMC protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:10460269 PMID:11193135 PMID:11703388 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects activity multiple interactions increases expression |
EXP ISO |
Nitric Oxide affects the activity of PPARA protein [[resveratrol results in increased activity of PPARA protein] which results in increased expression of NOS3 protein] which results in increased chemical synthesis of Nitric Oxide [Bezafibrate binds to and results in increased activity of PPARA protein] which results in increased abundance of Nitric Oxide; [Clofibrate binds to and results in increased activity of PPARA protein] which results in increased abundance of Nitric Oxide; Nitric Oxide deficiency inhibits the reaction [Clofibrate results in increased expression of PPARA protein] Nitric Oxide deficiency results in increased expression of PPARA mRNA; Nitric Oxide deficiency results in increased expression of PPARA protein |
CTD |
PMID:15018640 PMID:16054168 PMID:16411023 PMID:19834340 PMID:21791144 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
[rosiglitazone binds to and affects the activity of PPARG protein] which results in increased abundance of Nitric Oxide [1,1-bis(3'-indolyl)-1-(4-trifluoromethylphenyl)methane binds to and results in increased activity of PPARG protein] inhibits the reaction [Manganese results in increased chemical synthesis of Nitric Oxide] Nitric Oxide deficiency results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; ciglitazone inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; GW 1929 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; PPARG protein affects the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide] |
CTD |
PMID:12847270 PMID:16527820 PMID:17063326 PMID:18041089 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
Nitric Oxide results in increased expression of PPM1D mRNA |
CTD |
PMID:15126337 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Ppm1g |
protein phosphatase, Mg2+/Mn2+ dependent, 1G |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PPM1G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:25,153,556...25,173,763
Ensembl chr 6:25,153,556...25,173,761
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PPP3CA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PPP5C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prdm2 |
PR/SET domain 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of PRDM2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr 5:155,421,066...155,531,884
Ensembl chr 5:155,422,134...155,531,825
|
|
G |
Prim2 |
DNA primase subunit 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PRIM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
PRKAA1 protein affects the reaction [Fenofibrate results in increased abundance of Nitric Oxide] |
CTD |
PMID:20580385 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
Nitric Oxide deficiency promotes the reaction [Brimonidine Tartrate affects the localization of PRKCA protein] |
CTD |
PMID:12388232 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
EXP |
Nitric Oxide deficiency inhibits the reaction [Brimonidine Tartrate affects the localization of PRKCD protein] |
CTD |
PMID:12388232 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
2-mercaptomethyl-3-guanidinoethylthiopropionic acid inhibits the reaction [[PRL co-treated with furylacryloylalanylarginine co-treated with Testosterone] results in increased abundance of Nitric Oxide]; [PRL co-treated with furylacryloylalanylarginine co-treated with Testosterone] results in increased abundance of Nitric Oxide; [PRL co-treated with furylacryloylalanylarginine] results in increased abundance of Nitric Oxide; [PRL results in increased expression of CPD mRNA] which results in increased chemical synthesis of Nitric Oxide |
CTD |
PMID:21688280 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of PTGS1 mRNA] |
CTD |
PMID:21983654 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
EXP |
[Ouabain results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Nitric Oxide Nitric Oxide deficiency results in decreased expression of PTGS2 mRNA |
CTD |
PMID:18976649 PMID:21983654 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of PTK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of PTTG1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
EXP |
[Lipopolysaccharides results in increased activity of RAF1 protein] which results in decreased secretion of Nitric Oxide |
CTD |
PMID:19039081 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Ramp1 |
receptor activity modifying protein 1 |
increases expression |
EXP |
Nitric Oxide deficiency results in increased expression of RAMP1 mRNA; Nitric Oxide deficiency results in increased expression of RAMP1 protein |
CTD |
PMID:16326922 |
|
NCBI chr 9:91,765,481...91,816,152
Ensembl chr 9:91,781,285...91,816,151
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
multiple interactions increases expression |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein] Nitric Oxide deficiency results in increased expression of RAMP2 mRNA; Nitric Oxide deficiency results in increased expression of RAMP2 protein |
CTD |
PMID:16326922 |
|
NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
multiple interactions increases expression |
EXP |
Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]; Hydrochlorothiazide inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein] Nitric Oxide deficiency results in increased expression of RAMP3 mRNA; Nitric Oxide deficiency results in increased expression of RAMP3 protein |
CTD |
PMID:16326922 |
|
NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP1A protein] |
CTD |
PMID:16963453 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rap2a |
RAP2A, member of RAS oncogene family |
multiple interactions |
ISO |
Nitric Oxide promotes the reaction [ITGB2 protein results in increased activity of RAP2A protein] |
CTD |
PMID:16963453 |
|
NCBI chr15:97,596,848...97,597,338
Ensembl chr15:97,596,020...97,624,138
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
multiple interactions |
EXP |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] |
CTD |
PMID:16908409 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of RBBP6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
|
|
G |
Rcn1 |
reticulocalbin 1 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of RCN1 protein |
CTD |
PMID:19320461 |
|
NCBI chr 3:91,841,052...91,855,295
Ensembl chr 3:91,841,052...91,855,295
|
|
G |
Rdx |
radixin |
increases phosphorylation |
EXP |
Nitric Oxide deficiency results in increased phosphorylation of RDX protein |
CTD |
PMID:14732730 |
|
NCBI chr 8:52,379,494...52,437,673
Ensembl chr 8:52,379,494...52,437,678
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
EXP |
Nitric Oxide deficiency affects the localization of RELA protein |
CTD |
PMID:19631198 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions increases expression |
EXP |
[Nitric Oxide deficiency co-treated with Sodium Chloride, Dietary] results in increased expression of REN protein; Nebivolol inhibits the reaction [Nitric Oxide deficiency results in increased expression of REN protein] |
CTD |
PMID:7541960 PMID:10679504 PMID:12806161 PMID:15123544 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Retn |
resistin |
multiple interactions increases expression |
ISO EXP |
[[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA Nitric Oxide deficiency results in increased expression of RETN mRNA |
CTD |
PMID:17063326 PMID:18369347 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
Nitric Oxide deficiency affects the localization of and results in increased activity of RHOA protein |
CTD |
PMID:14732730 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl10a |
ribosomal protein L10A |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPL10A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357
|
|
G |
Rpl12 |
ribosomal protein L12 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:16,264,269...16,266,645
Ensembl chr 3:16,264,251...16,266,642
|
|
G |
Rpl3 |
ribosomal protein L3 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of RPL3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:111,622,255...111,627,640
Ensembl chr 7:111,621,610...111,636,468
|
|
G |
Rpl8 |
ribosomal protein L8 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPL8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482 Ensembl chr 3:108,622,324...108,628,482
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPLP0 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPLP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
|
|
G |
Rps12 |
ribosomal protein S12 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps14 |
ribosomal protein S14 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS14 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:54,227,854...54,232,638
Ensembl chr18:54,227,854...54,233,166
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS15 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450
|
|
G |
Rps20 |
ribosomal protein S20 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS20 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:16,819,095...16,820,476
Ensembl chr 5:16,819,304...16,820,475 Ensembl chr 9:16,819,304...16,820,475 Ensembl chr 3:16,819,304...16,820,475
|
|
G |
Rps26 |
ribosomal protein S26 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS26 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:1,057,332...1,058,882
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[resveratrol results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide; [Sirolimus results in decreased activity of RPS6KB1 protein] which results in increased abundance of Nitric Oxide |
CTD |
PMID:21544240 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145
|
|
G |
Rps8 |
ribosomal protein S8 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of RPS8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:130,630,362...130,632,932
Ensembl chr 5:130,629,716...130,633,268
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases abundance |
ISO |
HLA-DRB1 protein results in increased abundance of Nitric Oxide |
CTD |
PMID:17075829 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions increases secretion |
ISO EXP |
[S100B protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; PARP1 gene mutant form inhibits the reaction [S100B protein results in increased secretion of Nitric Oxide] |
CTD |
PMID:16376947 PMID:27444121 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Sap30bp |
SAP30 binding protein |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of SAP30BP mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:101,165,777...101,198,503
Ensembl chr10:101,165,856...101,198,502
|
|
G |
Scgb1a1 |
secretoglobin family 1A member 1 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of SCGB1A1 protein |
CTD |
PMID:15764486 |
|
NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610
|
|
G |
Sdc2 |
syndecan 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of SDC2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Nitric Oxide deficiency inhibits the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased expression of SELE protein]] |
CTD |
PMID:14762100 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Nitric Oxide results in increased expression of SETDB2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions decreases expression |
EXP |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPA1 mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPA1 mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sftpb |
surfactant protein B |
multiple interactions decreases expression |
EXP |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPB mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPB mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
multiple interactions decreases expression |
EXP |
bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPC mRNA]; PD 156707 inhibits the reaction [Nitric Oxide results in decreased expression of SFTPC mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
SIRT1 protein affects the reaction [INS protein results in increased secretion of Nitric Oxide]; SIRT1 protein affects the reaction [resveratrol inhibits the reaction [Glucose inhibits the reaction [INS protein results in increased secretion of Nitric Oxide]]] |
CTD |
PMID:20960276 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
multiple interactions affects expression |
EXP ISO |
Nitric Oxide promotes the reaction [[RASD1 protein binds to ACBD3 protein binds to SLC11A2 protein] which results in increased uptake of Iron] Nitric Oxide affects the expression of SLC11A2 protein alternative form |
CTD |
PMID:16232120 PMID:16908409 |
|
NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
EXP |
Nitric Oxide deficiency results in decreased expression of SLC40A1 protein |
CTD |
PMID:24184442 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
multiple interactions |
EXP |
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]] |
CTD |
PMID:12612912 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc5a2 |
solute carrier family 5 member 2 |
decreases activity |
EXP |
Nitric Oxide deficiency results in decreased activity of SLC5A2 protein |
CTD |
PMID:17940347 |
|
NCBI chr 1:182,847,185...182,853,309
Ensembl chr 1:182,847,106...182,853,306
|
|
G |
Slc7a7 |
solute carrier family 7 member 7 |
decreases abundance |
ISO |
SLC7A7 protein results in decreased abundance of Nitric Oxide |
CTD |
PMID:11544277 |
|
NCBI chr15:27,822,088...27,873,121
Ensembl chr15:27,822,091...27,865,648
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
[SMAD4 protein co-treated with SMAD3 protein] affects the susceptibility to Nitric Oxide; Nitric Oxide results in increased activity of [SMAD4 protein binds to SMAD3 protein] |
CTD |
PMID:15949472 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad4 |
SMAD family member 4 |
multiple interactions |
EXP |
[SMAD4 protein co-treated with SMAD3 protein] affects the susceptibility to Nitric Oxide; Nitric Oxide results in increased activity of [SMAD4 protein binds to SMAD3 protein] |
CTD |
PMID:15949472 |
|
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:24290359 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Snta1 |
syntrophin, alpha 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of SNTA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:142,876,285...142,906,737
Ensembl chr 3:142,876,296...142,906,709
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases abundance multiple interactions decreases response to substance |
ISO EXP |
SOD1 protein results in increased abundance of Nitric Oxide Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of SOD1 mRNA] SOD1 protein inhibits the reaction [[spermine nitric oxide complex results in increased abundance of Nitric Oxide] which results in increased abundance of Superoxides]; SOD1 protein inhibits the reaction [Nitric Oxide results in decreased activity of NOS3 protein]; SOD1 protein inhibits the reaction [Nitric Oxide results in increased abundance of Peroxynitrous Acid] Nitric Oxide deficiency results in decreased susceptibility to SOD1 protein mutant form |
CTD |
PMID:12489993 PMID:19845829 PMID:21443684 PMID:21983654 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression decreases abundance affects abundance multiple interactions |
EXP ISO |
Nitric Oxide deficiency results in increased expression of SOD2 protein SOD2 protein results in decreased abundance of Nitric Oxide SOD2 protein affects the abundance of Nitric Oxide [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 mRNA; [NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which results in increased expression of SOD2 protein 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein]; 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA]; [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of and results in increased activity of SOD2 protein; [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA; Dactinomycin inhibits the reaction [[2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased abundance of Nitric Oxide] which results in increased expression of SOD2 mRNA]; Nitric Oxide deficiency inhibits the reaction [Formaldehyde results in increased expression of SOD2 mRNA]; SOD2 protein inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitric Oxide]; tempol inhibits the reaction [Nitric Oxide deficiency results in increased expression of SOD2 protein] |
CTD |
PMID:9576743 PMID:14996425 PMID:15925750 PMID:19320461 PMID:20110409 PMID:21983654 PMID:23964924 More...
|
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of SPP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[resveratrol promotes the reaction [ESR1 protein binds to CAV1 protein binds to SRC protein]] which results in increased abundance of Nitric Oxide |
CTD |
PMID:18296501 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
STAT1 protein promotes the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:23106696 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
decreases expression multiple interactions |
ISO |
Nitric Oxide results in decreased expression of STAT5A protein STAT5A protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] |
CTD |
PMID:16886906 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
multiple interactions decreases expression |
ISO |
STAT5B protein affects the reaction [Nitric Oxide results in decreased expression of ACO1 mRNA] Nitric Oxide results in decreased expression of STAT5B protein |
CTD |
PMID:16886906 |
|
NCBI chr10:85,704,841...85,775,856
Ensembl chr10:85,705,670...85,775,668
|
|
G |
Suv39h2 |
SUV39H2 histone lysine methyltransferase |
increases expression |
ISO |
Nitric Oxide results in increased expression of SUV39H2 mRNA |
CTD |
PMID:23546878 |
|
NCBI chr17:74,756,290...74,775,332
Ensembl chr17:74,756,306...74,775,332
|
|
G |
Syn1 |
synapsin I |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of SYN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Taldo1 |
transaldolase 1 |
multiple interactions decreases abundance |
ISO |
Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of Nitric Oxide] |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tbca |
tubulin folding cofactor A |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of TBCA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:26,011,714...26,065,909
Ensembl chr 2:26,011,795...26,065,907
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions decreases expression |
ISO EXP |
[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC Nitric Oxide deficiency results in decreased expression of TFRC protein |
CTD |
PMID:24184442 PMID:24964743 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
candesartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of TGFB1 mRNA]; Nitric Oxide inhibits the reaction [Paraquat results in increased expression of TGFB1 protein] |
CTD |
PMID:15820443 PMID:16778335 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbd |
thrombomodulin |
multiple interactions decreases expression |
EXP |
candesartan inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]; Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein] |
CTD |
PMID:16778335 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression |
ISO |
Nitric Oxide results in decreased expression of TIMP2 mRNA; Nitric Oxide results in decreased expression of TIMP2 protein |
CTD |
PMID:18796497 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tinf2 |
TERF1 interacting nuclear factor 2 |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of TINF2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:29,170,663...29,178,015
Ensembl chr15:29,170,652...29,176,984
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression multiple interactions |
EXP ISO |
Nitric Oxide deficiency results in decreased expression of TJP1 protein [NOS2 protein results in increased chemical synthesis of Nitric Oxide] which results in decreased expression of TJP1 mRNA |
CTD |
PMID:15763998 PMID:25870319 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tk1 |
thymidine kinase 1 |
increases mutagenesis |
ISO |
Nitric Oxide results in increased mutagenesis of TK1 gene |
CTD |
PMID:22303861 PMID:28454271 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tle5 |
TLE family member 5, transcriptional modulator |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of TLE5 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
TLR4 gene mutant form inhibits the reaction [Fungal Polysaccharides results in increased abundance of Nitric Oxide]; TLR4 protein affects the reaction [Plant Extracts results in increased chemical synthesis of Nitric Oxide]; TLR4 protein affects the reaction [Polysaccharides results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:22687552 PMID:23246459 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases expression increases metabolic processing decreases abundance increases secretion |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; [IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL5 protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [NOS2 protein results in increased abundance of Nitric Oxide] affects the susceptibility to [IL1B protein co-treated with TNF protein co-treated with IFNG protein]; Acetylcysteine inhibits the reaction [TNF results in increased abundance of Nitric Oxide]; Alginic Acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; allicin inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Ascorbic Acid inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Dactinomycin inhibits the reaction [TNF results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; martentoxin, Buthus martensi inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; N,N-diacetylcystine inhibits the reaction [TNF protein results in decreased abundance of Nitric Oxide]; pyrrolidine dithiocarbamic acid promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]]; rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Nitric Oxide]; Wortmannin inhibits the reaction [Ciprofloxacin inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]] [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 mRNA] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] affects the expression of NOS2 protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; [[TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide] which results in decreased expression of RETN mRNA; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [Lipopolysaccharides co-treated with TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased secretion of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide; [TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; cobaltous chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Dexamethasone inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Estriol inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Guanidines analog inhibits the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; IL4 protein inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; lead chloride inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; manganese chloride promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Manganese promotes the reaction [[TNF protein co-treated with IFNG protein] promotes the reaction [NOS2 protein results in increased chemical synthesis of Nitric Oxide]]; Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]; Melitten inhibits the reaction [[TNF protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; NFKBIA protein affects the reaction [manganese chloride promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; NFKBIA protein affects the reaction [Manganese promotes the reaction [TNF protein co-treated with and results in increased chemical synthesis of IFNG protein co-treated with and results in increased chemical synthesis of Nitric Oxide]]; nickel chloride promotes the reaction [[[TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] affects the localization of Zinc]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT1 mRNA]; Nitric Oxide affects the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of MT2 mRNA]; NOS2 protein promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; NOS2 protein promotes the reaction [cobaltous chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; NOS2 protein promotes the reaction [nickel chloride promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]]; pimagedine inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased chemical synthesis of Nitric Oxide]; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of TNF protein] which results in increased chemical synthesis of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Quercetin inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; sodium arsenite inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Y 27632 promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide] Nitric Oxide deficiency results in increased expression of TNF protein; Nitric Oxide results in increased expression of TNF protein TNF protein results in increased metabolism of Nitric Oxide 7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; [IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; [IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide; [Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide; [TNF co-treated with IL1B co-treated with IFNG] results in increased abundance of Nitric Oxide; [TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide; Acetylcysteine inhibits the reaction [Nitric Oxide deficiency results in increased expression of TNF protein]; Diclofenac promotes the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; Genistein inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; KMUP 1 inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide]; Polyphenols inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; S-methylisothiopseudouronium inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; TNF protein affects the reaction [Lipopolysaccharides results in increased secretion of Nitric Oxide]; Vitamin E inhibits the reaction [[IL1B protein co-treated with TNF protein] results in increased chemical synthesis of Nitric Oxide]; zaprinast inhibits the reaction [TNF protein results in increased abundance of Nitric Oxide] TNF protein results in increased abundance of Nitric Oxide; TNF results in increased abundance of Nitric Oxide Nitric Oxide results in increased secretion of TNF protein; TNF protein results in increased secretion of Nitric Oxide |
CTD |
PMID:7519435 PMID:8341679 PMID:8903404 PMID:8975779 PMID:9388267 PMID:10706834 PMID:10909967 PMID:11063824 PMID:11282106 PMID:12612912 PMID:12723939 PMID:13678430 PMID:14617770 PMID:14623498 PMID:15223066 PMID:15451797 PMID:15485488 PMID:16168523 PMID:16366677 PMID:16492401 PMID:16754782 PMID:16968468 PMID:17026986 PMID:17067557 PMID:17157857 PMID:17729120 PMID:18206661 PMID:18207479 PMID:18369347 PMID:19393675 PMID:20626112 PMID:20708382 PMID:21943492 PMID:23439570 PMID:24086172 PMID:25766886 PMID:32613688 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation decreases expression affects response to substance increases glutathionylation increases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; Caffeine inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein]; wortmannin inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] [S-Nitroso-N-Acetylpenicillamine results in increased abundance of Nitric Oxide] which results in increased expression of TRP53 mRNA Nitric Oxide results in decreased expression of TRP53 protein [7-nitroindazole results in decreased chemical synthesis of Nitric Oxide] inhibits the reaction [Paraquat results in increased phosphorylation of TP53 protein]; [NOS2 protein results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein; [S-Nitrosoglutathione results in increased abundance of Nitric Oxide] which results in increased expression of TP53 protein TP53 protein affects the susceptibility to Nitric Oxide Nitric Oxide results in increased glutathionylation of TP53 protein Nitric Oxide results in increased expression of TP53 protein |
CTD |
PMID:7673702 PMID:8982730 PMID:9743513 PMID:10608825 PMID:14634119 PMID:15177039 PMID:15979383 PMID:16024610 PMID:17555331 PMID:20478973 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of TRP53BP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Nitric Oxide results in increased expression of TP53I3 mRNA |
CTD |
PMID:15126337 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
G |
Txndc5 |
thioredoxin domain containing 5 |
multiple interactions |
ISO |
[NOS3 protein polymorphism results in decreased chemical synthesis of Nitric Oxide] which affects the expression of TXNDC5 protein |
CTD |
PMID:19320461 |
|
NCBI chr17:26,289,880...26,318,025
Ensembl chr17:26,289,880...26,318,025
|
|
G |
Ubc |
ubiquitin C |
increases expression |
ISO |
Nitric Oxide deficiency results in increased expression of UBC mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of UBE2L3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862
|
|
G |
Ucn |
urocortin |
increases abundance |
EXP |
UCN protein results in increased abundance of Nitric Oxide |
CTD |
PMID:20237592 |
|
NCBI chr 6:25,238,120...25,238,950
Ensembl chr 6:25,238,120...25,238,950
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression increases secretion |
EXP |
Nitric Oxide deficiency results in decreased expression of VEGFA mRNA VEGFA protein results in increased secretion of Nitric Oxide |
CTD |
PMID:15249212 PMID:16733097 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
EXP |
Nitric Oxide results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
XDH protein promotes the reaction [[Raloxifene Hydrochloride results in decreased expression of NOS2 protein] which results in decreased chemical synthesis of Nitric Oxide] |
CTD |
PMID:20888885 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression increases expression |
ISO |
Nitric Oxide results in decreased expression of XIAP mRNA Nitric Oxide results in increased expression of XIAP protein |
CTD |
PMID:14634119 PMID:15126337 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zfp422 |
zinc finger protein 422 |
decreases expression |
ISO |
Nitric Oxide deficiency results in decreased expression of ZFP422 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:149,885,805...149,893,287
Ensembl chr 4:149,885,600...149,893,257
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
ABCC1 protein affects the reaction [AGT protein results in increased abundance of Superoxides] |
CTD |
PMID:17272743 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Aco1 |
aconitase 1 |
decreases activity multiple interactions |
ISO |
Superoxides results in decreased activity of ACO1 protein [SOD1 protein results in decreased abundance of Superoxides] which results in increased expression of ACO1 protein |
CTD |
PMID:28542246 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions decreases activity |
EXP |
[[[Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron] which co-treated with Hydrogen Peroxide] results in increased chemical synthesis of Hydroxyl Radical; [Superoxides results in decreased activity of ACO2 protein] which results in increased abundance of Iron |
CTD |
PMID:16162655 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
ISO |
ADA protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] |
CTD |
PMID:10947063 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases abundance |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; ABCC1 protein affects the reaction [AGT protein results in increased abundance of Superoxides]; acetovanillone inhibits the reaction [AGT protein results in increased abundance of Superoxides]; ATOX1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; NOS3 protein affects the reaction [AGT protein results in increased abundance of Superoxides]; Propranolol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; SOD1 protein inhibits the reaction [AGT protein results in increased abundance of Superoxides]; SOD3 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] SOD1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] AGT protein modified form results in increased abundance of Superoxides; AGT protein results in increased abundance of Superoxides 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; acetovanillone inhibits the reaction [AGT protein results in increased abundance of Superoxides]; bisindolylmaleimide I inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]; diphenyleneiodonium inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]]; tempol inhibits the reaction [Brimonidine Tartrate promotes the reaction [AGT protein results in increased abundance of Superoxides]] |
CTD |
PMID:12606818 PMID:16531806 PMID:16864745 PMID:17272743 PMID:17391658 PMID:18250367 PMID:18768397 PMID:20881940 PMID:22753205 PMID:24363997 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
[Mevinphos results in increased activity of AGTR1A protein] promotes the reaction [NOX1 protein results in increased abundance of Superoxides] |
CTD |
PMID:23824088 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[AKR1C3 protein results in increased reduction of 9,10-phenanthrenequinone] which results in increased abundance of Superoxides; [AKR1C3 protein results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:19442656 PMID:21910479 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:21910479 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Alb |
albumin |
increases chemical synthesis multiple interactions |
ISO |
ALB protein modified form results in increased chemical synthesis of Superoxides Etomidate promotes the reaction [ALB protein modified form results in increased chemical synthesis of Superoxides] |
CTD |
PMID:25421967 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions |
ISO |
[ALDH5A1 gene mutant form results in increased susceptibility to 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] which results in increased abundance of Superoxides; [ALDH5A1 gene mutant form results in increased susceptibility to NCS 382] which results in increased abundance of Superoxides |
CTD |
PMID:29031482 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Apoe |
apolipoprotein E |
increases chemical synthesis increases abundance multiple interactions |
ISO |
APOE gene mutant form results in increased chemical synthesis of Superoxides APOE gene mutant form results in increased abundance of Superoxides imisopasem manganese inhibits the reaction [APOE gene mutant form results in increased chemical synthesis of Superoxides]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [APOE gene mutant form results in increased abundance of Superoxides] |
CTD |
PMID:11397713 PMID:12871831 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases chemical synthesis |
ISO |
3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine inhibits the reaction [APP gene mutant form results in increased chemical synthesis of Superoxides]; GW 501516 inhibits the reaction [APP gene mutant form results in increased chemical synthesis of Superoxides]; Resveratrol inhibits the reaction [APP protein results in increased abundance of Superoxides] |
CTD |
PMID:16212921 PMID:22886847 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Superoxides promotes the reaction [methylselenic acid results in decreased expression of AR protein] |
CTD |
PMID:16928829 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
multiple interactions |
ISO |
1-Butanol inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 1-Butanol inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; 2,3-Diphosphoglycerate inhibits the reaction [ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]]; ARF6 protein affects the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides]; ARF6 protein mutant form promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Superoxides] |
CTD |
PMID:10931844 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects abundance |
ISO |
ARRB2 protein affects the abundance of Superoxides |
CTD |
PMID:16210646 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
multiple interactions |
ISO |
ATOX1 protein inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:22753205 |
|
NCBI chr10:39,564,855...39,579,892
Ensembl chr10:39,564,857...39,579,950
|
|
G |
Atp7a |
ATPase copper transporting alpha |
increases abundance multiple interactions |
ISO |
ATP7A mutant form results in increased abundance of Superoxides [ATP7A protein results in increased activity of SOD3 protein] which results in decreased chemical synthesis of Superoxides; ATP7A gene mutant form promotes the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]; ATP7A protein inhibits the reaction [Streptozocin results in increased chemical synthesis of Superoxides]; tempol inhibits the reaction [ATP7A mutant form promotes the reaction [AGT protein results in increased abundance of Superoxides]] |
CTD |
PMID:18768397 PMID:23884884 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
C5 |
complement C5 |
multiple interactions increases abundance |
ISO |
8-(4-sulfophenyl)theophylline promotes the reaction [C5 protein modified form results in increased abundance of Superoxides]; Theophylline inhibits the reaction [C5 protein modified form results in increased abundance of Superoxides]; Theophylline promotes the reaction [C5 protein modified form results in increased abundance of Superoxides] |
CTD |
PMID:10947063 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[[Xanthine co-treated with XDH protein] results in increased abundance of Superoxides] which results in increased secretion of TGFB1 protein]; CAT protein inhibits the reaction [Superoxides results in increased secretion of TGFB1 protein] |
CTD |
PMID:19268487 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbs |
cystathionine beta synthase |
affects abundance multiple interactions |
ISO |
CBS protein affects the abundance of Superoxides SMPD1 protein affects the reaction [CBS protein affects the abundance of Superoxides] |
CTD |
PMID:23024785 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Superoxides affects the reaction [Fructose results in increased secretion of CCL2 protein] Superoxides results in increased expression of CCL2 mRNA 1,3-dimethylthiourea inhibits the reaction [Superoxides results in increased expression of CCL2 mRNA] |
CTD |
PMID:8856246 PMID:19158351 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd38 |
CD38 molecule |
affects localization multiple interactions |
ISO |
Superoxides affects the localization of CD38 protein tempol inhibits the reaction [Superoxides affects the localization of CD38 protein] |
CTD |
PMID:23940720 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP |
CRP protein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Superoxides] |
CTD |
PMID:9767445 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions increases abundance |
ISO EXP |
CYBA protein promotes the reaction [arsenite results in increased abundance of Superoxides] CYBA protein results in increased abundance of Superoxides |
CTD |
PMID:10720412 PMID:14871555 PMID:20523355 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
CYBB mutant form inhibits the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB protein affects the reaction [Folic Acid deficiency results in increased chemical synthesis of Superoxides]; CYBB protein affects the reaction [Homocysteine results in increased abundance of Superoxides]; CYBB protein promotes the reaction [[Doxorubicin co-treated with NADP] results in increased abundance of Superoxides] IL1B protein promotes the reaction [CYBB protein results in increased chemical synthesis of Superoxides] |
CTD |
PMID:16354686 PMID:17275678 PMID:20116427 PMID:21647593 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases abundance |
ISO |
CYP1A1 protein results in increased abundance of Superoxides |
CTD |
PMID:20634294 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions increases chemical synthesis |
ISO |
[DCXR protein results in increased metabolism of Vitamin K 3] which results in increased chemical synthesis of Superoxides; Diacetyl inhibits the reaction [[DCXR protein results in increased metabolism of Vitamin K 3] which results in increased chemical synthesis of Superoxides] DCXR protein results in increased chemical synthesis of Superoxides |
CTD |
PMID:28595002 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases abundance increases expression multiple interactions |
ISO |
DDIT3 protein results in increased abundance of Superoxides Superoxides results in increased expression of DDIT3 mRNA; Superoxides results in increased expression of DDIT3 protein [DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGA3 protein; [DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGB1 protein |
CTD |
PMID:16400006 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases abundance |
EXP ISO |
[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides; Catechin inhibits the reaction [EDN1 protein results in increased abundance of Superoxides]; NOS3 protein affects the reaction [[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides]; Polyphenols inhibits the reaction [[EDN1 protein co-treated with Calcimycin] results in increased abundance of Superoxides] NOX1 mutant form inhibits the reaction [EDN1 protein results in increased abundance of Superoxides] |
CTD |
PMID:20977430 PMID:23940720 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
affects abundance |
EXP |
EDNRA protein affects the abundance of Superoxides |
CTD |
PMID:12600921 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases abundance |
ISO |
EP300 protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
EPO protein inhibits the reaction [[NOS3 protein co-treated with sapropterin deficiency] results in increased chemical synthesis of Superoxides] |
CTD |
PMID:25490417 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions decreases abundance increases abundance |
ISO |
3-aminobenzamide inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides]; NU 1025 inhibits the reaction [ERCC6 gene mutant form results in increased abundance of Superoxides] ERCC6 protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol binds to and results in increased activity of ESR1 protein] which results in decreased abundance of Superoxides; [ESR1 protein results in increased susceptibility to Estradiol] which results in increased abundance of Superoxides; ESR1 protein affects the reaction [Estradiol results in decreased chemical synthesis of Superoxides] |
CTD |
PMID:18354059 PMID:23000059 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions increases abundance |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides] |
CTD |
PMID:27385396 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Superoxides affects the reaction [Glucose results in increased expression of FN1 mRNA] |
CTD |
PMID:16572112 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
SOD2 protein inhibits the reaction [Superoxides results in increased expression of FOS mRNA] |
CTD |
PMID:9067545 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO EXP |
SOD2 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] UCP1 protein inhibits the reaction [[Glucose results in increased chemical synthesis of Superoxides] which results in decreased activity of GAPDH protein] |
CTD |
PMID:11050244 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gas5 |
growth arrest specific 5 |
increases expression |
ISO |
Superoxides results in increased expression of GAS5 mRNA; Superoxides results in increased expression of GAS5 protein |
CTD |
PMID:16400006 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
affects abundance |
ISO |
GCH1 protein affects the abundance of Superoxides |
CTD |
PMID:21963838 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases abundance increases abundance |
ISO EXP |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides] HMOX1 protein results in decreased abundance of Superoxides [tetrathiomolybdate analog results in increased abundance of Superoxides] which results in increased reduction of HMOX1 protein [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in decreased abundance of Superoxides; [cobaltous chloride results in increased expression of HMOX1 protein] which results in decreased abundance of Superoxides; [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Superoxides; [tin mesoporphyrin results in decreased activity of HMOX1 protein] which results in increased abundance of Superoxides; Deferoxamine inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides]; zinc protoporphyrin inhibits the reaction [HMOX1 protein results in increased abundance of Superoxides] |
CTD |
PMID:15821039 PMID:16959961 PMID:18073186 PMID:18178725 PMID:18334666 PMID:19323979 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases abundance multiple interactions |
ISO |
HRAS protein mutant form results in increased abundance of Superoxides [HRAS protein mutant form results in increased abundance of Superoxides] which results in decreased susceptibility to TNF protein |
CTD |
PMID:11313892 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions decreases abundance |
ISO |
[tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex results in decreased abundance of Superoxides] which results in decreased expression of HSPB1 protein HSPB1 protein results in decreased abundance of Superoxides |
CTD |
PMID:14975446 PMID:19193722 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Ier3 |
immediate early response 3 |
affects chemical synthesis |
ISO |
IER3 protein affects the chemical synthesis of Superoxides |
CTD |
PMID:20713914 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases abundance |
ISO |
IGF1 protein results in decreased abundance of Superoxides |
CTD |
PMID:22843358 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
diphenyleneiodonium inhibits the reaction [IL1B protein results in increased abundance of Superoxides]; IL1B protein promotes the reaction [CYBB protein results in increased chemical synthesis of Superoxides] |
CTD |
PMID:16354686 PMID:21211511 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]; Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]; ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] |
CTD |
PMID:16238794 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides] |
CTD |
PMID:20457604 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Itga3 |
integrin subunit alpha 3 |
multiple interactions |
ISO |
[DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGA3 protein |
CTD |
PMID:16400006 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
ISO |
[DDIT3 protein results in increased abundance of Superoxides] which results in decreased expression of ITGB1 protein |
CTD |
PMID:16400006 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP ISO |
Superoxides affects the reaction [Glucose results in increased phosphorylation of JUN protein] Superoxides results in increased expression of JUN mRNA SOD2 protein inhibits the reaction [Superoxides results in increased expression of JUN mRNA] |
CTD |
PMID:9067545 PMID:16572112 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kat2a |
lysine acetyltransferase 2A |
decreases abundance |
ISO |
KAT2A protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr10:85,632,216...85,640,561
Ensembl chr10:85,632,216...85,640,166
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
decreases abundance |
ISO |
KAT2B protein results in decreased abundance of Superoxides |
CTD |
PMID:25440059 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kdr |
kinase insert domain receptor |
increases phosphorylation |
ISO |
Superoxides results in increased phosphorylation of KDR protein |
CTD |
PMID:19571580 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
ISO |
acetovanillone inhibits the reaction [LEP protein results in increased abundance of Superoxides]; BQ 788 inhibits the reaction [LEP protein results in increased abundance of Superoxides]; cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [LEP protein results in increased abundance of Superoxides] [LEP protein results in increased oxidation of Fatty Acids] which results in increased chemical synthesis of Superoxides |
CTD |
PMID:11342529 PMID:16380530 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
multiple interactions increases abundance |
ISO |
acetovanillone inhibits the reaction [LEPR gene mutant form results in increased abundance of Superoxides]; resveratrol inhibits the reaction [LEPR gene mutant form results in increased abundance of Superoxides] |
CTD |
PMID:19478208 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK1 protein] Superoxides results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16572112 PMID:19268487 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
Superoxides affects the reaction [Glucose results in increased phosphorylation of MAPK3 protein] Superoxides results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16572112 PMID:19268487 |
|
NCBI chr 1:181, | |